Methods for Treating Cancer with Antagonist Anti-PD-1 Antibodies

Specific CDRs of anti-PD-1 antibodies, formulated with histidine, sucrose, polysorbate-20, and EDTA, enhance tumor immunity by inhibiting PD-1, achieving a 15% overall response rate in advanced cancers, particularly in PD-L1 high non-small cell lung cancer and melanoma.

JP7579705B2Active Publication Date: 2024-11-08JANSSEN BIOTECH INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020540403
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-01-18
Filing Date
2019-01-19
Publication Date
2024-11-08
Estimated Expiration
2039-01-19

AI Technical Summary

Technical Problem

Existing anti-PD-1 antibodies for cancer treatment have low response rates, with only about 15-20% efficacy in pretreated patients, necessitating the development of more effective therapeutic agents to enhance immune responses against tumors.

Method used

Administration of specific heavy and light chain complementarity determining regions (CDRs) of anti-PD-1 antibodies, formulated with histidine, sucrose, polysorbate-20, and EDTA, at doses ranging from 80 mg to 1000 mg every 2-6 weeks, to inhibit the immunosuppressive activity of PD-1 and stimulate antitumor immunity.

Benefits of technology

The formulation achieves an overall response rate of at least 15% in advanced solid tumors, with higher response rates in PD-L1 high non-small cell lung cancer and melanoma, demonstrating improved efficacy compared to standard treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579705000013
    Figure 0007579705000013
  • Figure 0007579705000014
    Figure 0007579705000014
  • Figure 0007579705000015
    Figure 0007579705000015
Patent Text Reader

Abstract

The present invention relates to antagonistic anti-PD-1 antibodies, formulations of antagonistic anti-PD-1 antibodies, and methods of treating cancer with anti-PD-1 antibody drug products.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antagonistic anti-PD-1 antibodies, formulations of antagonistic anti-PD-1 antibodies, and methods of treating cancer with anti-PD-1 antibody drug products.

[0002] (Sequence Listing) This application contains a Sequence Listing submitted via EFS-Web, the entire contents of which are incorporated herein by reference. The ASCII text file, created on January 18, 2019, has the file name JBI5152WOPCT1_ST25.txt and is 12 kilobytes in size. [Background technology]

[0003] The immune system is tightly controlled by a network of co-stimulatory and co-inhibitory ligands and receptors. These molecules provide secondary signals for T cell activation, providing a balanced network of positive and negative signals to maximize immune responses against infections and tumors while limiting immunity against self (Wang et al., (Epub Mar. 7, 2011) J Exp Med 208(3):577:-92; Lepenies et al., (2008) Endocr Metab Immune Disord Drug Targets 8:279-288). Immune checkpoint therapy, which targets co-inhibitory pathways in T cells to promote anti-tumor immune responses, has led to advances in the clinical care of cancer patients.

[0004] PD-1 inhibits CD4+ in the tumor microenvironment (TME). + and CD8 +PD-1 is a negative immune checkpoint molecule that suppresses T cell function. PD-1 engages with its ligands (PD-L1 and PD-L2) to inhibit multiple pathways downstream of T cell receptor signaling, thereby driving T cell anergy and exhaustion in tumors, leading to T cell survival, growth, and proliferation, attenuation of effector function, and metabolic changes. Preclinical studies have demonstrated that PD-1 pathway blockade can reverse T cell exhaustion and stimulate antitumor immunity.

[0005] Anti-PD-1 / PD-L1 antibodies have been demonstrated to induce clinical responses in patients with multiple solid tumors, but response rates remain fairly low, approximately 15%-20% in pretreated patients (Swaika et al., (2015) Mol Immunol. doi:10.1016 / j.molimm.2015.02.009). Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, new therapeutic agents are needed that inhibit the immunosuppressive activity of checkpoint inhibitors such as PD-1, which are used in cancer immunotherapy. [Means for solving the problem]

[0007] The present invention provides a method of treating cancer, comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg.

[0008] The present invention also provides About 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); A lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; A lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or Also provided is a pharmaceutical composition comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients.

[0009] The present invention also relates to a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5), about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); A lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; A lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or Also provided is a drug product comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients.

[0010] The present invention also provides a composition comprising about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5), for the treatment of cancer. about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); A lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; A lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or Also provided is a drug product comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. [Brief description of the drawings]

[0011] [Figure 1] Figure 1 shows the mean serum concentrations (μg / ml) of JNJ-63723283 (cetrelimab) over time in subjects receiving 80 mg, 240 mg, 460 mg, 480 mg, or 800 mg once every 2 weeks (q2w) or once every 4 weeks (q4w), as indicated. The number of patients dosed (n) is indicated in parentheses. [Diagram 2]Figure 1 shows the percentage (%) of PD-1 receptor occupancy of JNJ-63723283 (cetrelimab) on CD3+ circulating T cells over time (indicated by doses administered 1-39) in subjects receiving 240 mg cetrelimab q2w. Pre: pre-dose, EOI+2H: end of infusion + 2 hours. EOI+1H: end of infusion + 1 hour. EOT: end of treatment. [Diagram 3] Figure 1 shows the percentage (%) of PD-1 receptor occupancy of JNJ-63723283 (cetrelimab) on CD3+ circulating T cells over time (indicated by doses administered 1-14) in subjects receiving 480 mg cetrelimab q4w. Pre: pre-dose, EOI+2H: end of infusion + 2 hours. EOI+1H: end of infusion + 1 hour. EOT: end of treatment. [Figure 4] Figure 1 shows the time course of T cell activation in patients receiving JNJ-63723283 (cetrelimab) at 240 mg (solid line) once every 2 weeks (Q2W) or 480 mg (dashed line) once every 4 weeks (Q4W). A ratio of 1 indicates maximum T cell activation. D=dose, EOT=end of treatment (varies by patient), FU=observation, Pre=pre-infusion, Q2W=q2w, Q4W=q4w, SEB=staphylococcal enterotoxin B. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if fully set forth.

[0013] It should be understood that the terms used herein are used only for the purpose of describing the embodiments and are not intended to be limiting. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.

[0014] Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, exemplary materials and methods are described herein. In describing and claiming the present invention, the following terminology is used.

[0015] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a cell" includes a combination of two or more cells, and the like.

[0016] The transitional phrases "comprising," "consisting essentially of," and "consisting" are intended to connote their generally accepted meanings in patent language, i.e., (i) "comprising" is synonymous with "comprising," "containing," or "characterized by," is inclusive or open-ended, and does not exclude other unrecited elements or method steps, (ii) "consisting of" excludes any element, step, or ingredient not specified in the claim, and (iii) "consisting essentially of" limits the scope of the claim to the materials or steps specified, and those that do not materially affect the "basic and novel characteristic(s)" of the claimed invention. An embodiment described with respect to the phrase "comprising" (or its equivalents) also provides as an embodiment what is described independently with respect to "consisting of" and "consisting essentially of."

[0017] "Antagonist" or "antagonistic" refers to an anti-PD1 antibody that, upon binding to PD-1, inhibits at least one biological activity mediated by the PD-1 ligands PD-L1 or PD-L2. An anti-PD-1 antibody is an antagonist when at least one biological activity mediated by PD-L1 or PD-L2 is inhibited by at least about 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% more than in the absence of the antagonist (e.g., a negative control), or when the inhibition is statistically significant compared to the inhibition in the absence of the antagonist. Exemplary biological activities mediated by the binding of PD-L1 or PD-L2 to PD-1 include inhibition of antigen-specific CD4 + and / or CD8 + T cell inhibition. Thus, antagonist antibodies relieve PD-L1-mediated suppression, resulting in an enhanced immune response.

[0018] "PD-1" means human programmed cell death protein 1 (PD-1). PD-1 is also known as CD279 or PDCD1. The amino acid sequence of mature human PD-1 (without the signal sequence) is set forth in SEQ ID NO:11. The extracellular domain spans residues 1-150 of SEQ ID NO:11, the transmembrane domain spans residues 151-171 of SEQ ID NO:11, and the cytoplasmic domain spans residues 172-268 of SEQ ID NO:11.

[0019] SEQ ID NO:11 PGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL

[0020] The term "antibody" has a broad meaning and includes immunoglobulin molecules of any class, IgA, IgD, IgE, IgG, and IgM, or subclasses IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4, and containing either kappa (κ) or lambda (λ) light chains. Antibodies include monoclonal antibodies, full-length antibodies, antigen-binding fragments, bispecific or multispecific antibodies, dimeric, tetrameric, or multimeric antibodies, single-chain antibodies, domain antibodies, and modified configurations of any other immunoglobulin molecule containing antigen-binding fragments of the required specificity. A "full-length antibody" consists of two heavy chains (HC) and two light chains (LC) interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (consisting of domains CH1, hinge, CH2, and CH3). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). VH and VL can be further divided into regions of hypervariability called complementarity determining regions (CDRs) that are interspersed with framework regions (FRs). Each VH and VL consists of three CDRs and four FR fragments arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Antibodies include antibodies generated using a variety of techniques, including antibodies generated from immunized mice or rats, or antibodies identified from phage or mammalian display libraries as described herein.

[0021] A "complementarity determining region (CDR)" is a region of an antibody that binds to an antigen. There are three CDRs (HCDR1, HCDR2, and HCDR3) in VH, and three CDRs (LCDR1, LCDR2, and LCDR3) in VL. CDRs can be defined using a variety of descriptions, such as Kabat (Wu et al. (1970) J Exp Med 132:211-50) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), Chothia (Chothia et al. (1987) J Mol Biol 196:901-17), IMGT (Lefranc et al. (2003) Dev Comp Immunol 27:55-77), and AbM (Martin and Thornton (1996) J Bmol Biol 263:800-15). Various descriptions and their correspondence with the numbering of the variable regions have been described (see, for example, Lefranc et al. (2003) Dev Comp Immunol 27:55-77; Honegger and Pluckthun, (2001) J Mol Biol 309:657-70; International ImMunoGeneTics (IMGT) database; web source, http: / / www_imgt_org). Available programs such as abYsis by UCL Business PLC can be used to describe the CDRs. As used herein, the terms "CDR", "HCDR1", "HCDR2", "HCDR3", "LCDR1", "LCDR2" and "LCDR3" include CDRs defined by any of the methods of Kabat, Chothia, IMGT or AbM as described above, unless otherwise expressly stated in the specification.

[0022] "Antigen-binding fragment" refers to a portion of an immunoglobulin molecule that retains the antigen-binding properties of the parent full-length antibody. Exemplary antigen-binding fragments are heavy chain complementarity determining regions (HCDRs) 1, 2, and / or 3, light chain complementarity determining regions (LCDRs) 1, 2, and / or 3, VH, VL, VH and VL, Fab, F(ab')2, Fd, and Fv fragments, and domain antibodies (dAbs) consisting of either one VH domain or one VL domain. The VH and VL domains can be linked together via synthetic linkers to form various types of single chain antibody designs in which the VH / VL domains pair intramolecularly or intermolecularly when the VH and VL domains are expressed by separate chains to form monovalent antigen-binding sites such as single chain Fvs (scFvs) or diabodies. For example, they are described in WO 1998 / 44001, WO 1988 / 01649, WO 1994 / 13804 and WO 1992 / 01047.

[0023] "Humanized antibody" refers to an antibody in which the CDR sequences are derived from a non-human species and the framework is derived from a human immunoglobulin sequence. A humanized antibody may contain substitutions in the framework, so the framework may not be an exact copy of the sequence of an expressed human immunoglobulin or human immunoglobulin germline gene. An antibody in which at least one CDR is derived from a non-human species and at least one framework is derived from a human immunoglobulin sequence is a humanized antibody. A humanized antibody may contain substitutions in the framework, so the framework may not be an exact copy of the sequence of an expressed human immunoglobulin or human immunoglobulin germline gene.

[0024] "Human antibody" refers to an antibody that is optimized to elicit a minimal immune response when administered to a human subject. The variable regions of a human antibody are derived from human germline immunoglobulin sequences. If the antibody contains a constant region or a portion of a constant region, the constant region is also derived from human germline immunoglobulin sequences.

[0025] A human antibody comprises a heavy or light chain variable region "derived from" a human germline immunoglobulin sequence if the variable region of the antibody is obtained from a system that uses human germline immunoglobulin genes. Exemplary such systems are human immunoglobulin gene libraries displayed on phage or mammalian cells, and transgenic non-human animals such as mice, rats, or chickens that have human immunoglobulin loci. A "human antibody" typically contains amino acid differences when compared to immunoglobulins expressed in humans due to differences between the systems used to obtain the antibodies and human immunoglobulin loci, the introduction of naturally occurring somatic mutations, and the deliberate introduction of substitutions into the framework or CDRs. A "human antibody" is typically about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by a human germline immunoglobulin sequence. In some cases, a "human antibody" may contain a consensus framework sequence obtained from human framework sequence analysis, e.g., as described in (Knappik et al. (2000) J Mol Biol 296:57-86), or a synthetic HCDR3 incorporated into a phage-displayed human immunoglobulin gene library, e.g., as described in (Shi et al. (2010) J Mol Biol 397:385-96) and in WO 2009 / 085462. Antibodies in which the CDRs are derived from non-human species are not included in the definition of "human antibody."

[0026] "Monoclonal antibody" refers to an antibody population with a single amino acid composition in each antibody chain, except for possible known modifications, such as removal of the C-terminal lysine from the antibody heavy chain, or post-translational modification(s) of amino acids, such as methionine oxidation, or modification by deamidation of asparagine or glutamine. Monoclonal antibodies usually specifically bind to one antigenic epitope, while bispecific or multispecific monoclonal antibodies specifically bind to two or more different antigenic epitopes. Monoclonal antibodies may have heterogeneous glycosylation within the antibody population. Monoclonal antibodies may be monospecific or multispecific, or monovalent, bivalent, or multivalent. Bispecific antibodies are included in the term monoclonal antibody.

[0027] "Isolated" refers to a protein that has been subjected to at least one purification or isolation step, as well as to a homogenous population of molecules (e.g., a protein such as a synthetic polynucleotide or an antibody) that have been substantially separated and / or purified from other components of the system in which the molecule is produced, such as a recombinant cell. An "isolated antibody" refers to an antibody that is substantially free of other cellular material and / or chemicals, and includes antibodies that have been isolated to greater degrees of purity, e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% purity.

[0028] "Cancer cell" or "tumor cell" refers to a cancerous, precancerous, or transformed cell that has a phenotypic change that is either spontaneous or induced, either in vivo, ex vivo, or in tissue culture. These changes do not necessarily involve the incorporation of new genetic material. Transformation can occur by infection with a transforming virus and incorporation of new genomic nucleic acid, incorporation of exogenous nucleic acid, or can occur spontaneously or after exposure to a carcinogen, which mutates endogenous genes. Transformation / cancer is exemplified by morphological changes, cellular immortalization, aberrant growth control, formation of lesions, proliferation, malignant lesions, modulation of tumor-specific marker levels, invasiveness, tumor growth in suitable animal hosts such as nude mice, and the like, in vitro, in vivo, and ex vivo (Freshney, Culture of Animal Cells: A Manual of Basic Technique (3rd ed., 1994)).

[0029] "Cancer" refers to a broad group of different diseases characterized by the uncontrolled growth of abnormal cells in the body. Uncontrolled cell division and growth leads to the formation of malignant tumors that invade adjacent tissues and may also metastasize to distant parts of the body via the lymphatic system or bloodstream. "Cancer" or "cancerous tissue" may include tumors.

[0030] "About" means within an acceptable range of error for a particular value as determined by one of ordinary skill in the art, which will depend in part on the limitations of the method, i.e., measurement system, by which the value is measured or determined. Unless expressly stated otherwise in the Examples or elsewhere in the specification in the context of a particular assay, result, or embodiment, "about" means within one standard deviation or a range of up to 5%, whichever is greater, according to practice in the art.

[0031] A "subject" includes any human or non-human animal. A "non-human animal" includes any vertebrate, e.g., mammals and non-mammals, e.g., non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, and reptiles. The terms "subject" and "patient" can be used interchangeably herein.

[0032] "Treating" or "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent or slow (alleviate) undesirable physiological changes or disorders, such as the growth and / or spread of tumor cells. Beneficial or desired clinical results include alleviation of symptoms, shrinkage of tumor size, reduction in the extent of disease, stable (i.e., not worsening) disease state, whether detectable or undetectable, delay or slowing of disease progression, improvement or mitigation of disease state, and remission (whether partial or total). "Treatment" can also mean prolonging the survival of a subject compared to the expected survival if the subject were not receiving treatment. Those in need of treatment include those already with a condition or disease, as well as those prone to having a condition or disease, or those in whom a condition or disease is to be prevented.

[0033] "Therapeutically effective amount" refers to an amount effective to achieve a desired therapeutic result at the required dosage and duration. The therapeutically effective amount may vary depending on factors such as the individual's condition, age, sex, and weight, as well as the ability of a therapeutic agent or combination of therapeutic agents to elicit a desired response in an individual. Exemplary factors of an effective therapeutic agent or combination of therapeutic agents include, for example, improved health of the patient.

[0034] An "anti-PD-1 antibody" refers to an antibody that specifically binds to PD-1.

[0035] "Specifically binds" or "specific binding" or "binding" refers to an antibody that binds to an antigen (e.g., PD-1) or an epitope within an antigen with higher affinity than to other antigens. Typically, an antibody binds to an antigen with a binding affinity of about 1×10 -8 M or less, for example, about 1×10 -9 M or less, approximately 1×10 -10 M or less, approximately 1×10 -11 M or less, or about 1 x 10 -12 The equilibrium dissociation constant (K D ) to an antigen or an epitope within such an antigen, whereas for binding to a non-specific antigen (e.g., BSA casein), the K D At least 100 times smaller than K D Join with K D can be measured using standard procedures. However, antibodies that specifically bind to an antigen or an epitope within an antigen may have cross-reactivity to other related antigens, e.g., the same antigen (homologs) from other species, such as humans or monkeys, e.g., Macaca fascicularis (cynomolgus monkey, cyno), Pan troglodytes (chimp), or Callithrix jacchus (common marmoset, marmoset).

[0036] "Dosage" refers to information about the amount of therapeutic agent taken by a subject, and the frequency of times that treatment is taken by the subject.

[0037] "Dose" refers to the amount or quantity of therapeutic agent taken at any one time.

[0038] "Relapse" refers to the return of a disease or signs and symptoms of a disease after a period of improvement following previous treatment with a therapeutic agent.

[0039] "Refractory" refers to a disease that does not respond to treatment. A refractory disease may be resistant to treatment before or at the start of treatment, or a refractory disease may become resistant during treatment.

[0040] "Drug Substance" or "DS" refers to any substance or mixture of substances that is intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes the active ingredient of that drug product. Such substances are intended to provide pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.

[0041] "Drug product" or "DP" refers generally, but not necessarily, to a finished dosage form, e.g., a tablet, capsule, or solution, that contains an active pharmaceutical ingredient (e.g., a drug substance) along with inactive ingredients.

[0042] "Wild-type BRAF" refers to the serine / threonine protein kinase B-raf having the amino acid sequence set forth in UniProt accession number P15056.

[0043] "Mutant" refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide by one or more modifications, such as one or more substitutions, insertions, or deletions.For example, the reference BRAF polypeptide is wild-type BRAF.Mutations are indicated using well-known numbering systems, for example, V600E refers to the substitution of glutamic acid for valine at position 600.

[0044] "Immune condition" or "immune disorder" includes, for example, pathological inflammation, inflammatory disorders, and autoimmune disorders or diseases. "Immune condition" also refers to infections, persistent infections, and proliferative conditions such as cancers, tumors, and angiogenesis, including infections, tumors, and cancers that resist eradication by the immune system.

[0045] The present invention provides a method of treating cancer comprising providing an antagonist anti-PD1 antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 for administration to a subject diagnosed with cancer at a dosage of about 80 mg to about 1000 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks, and administering the antagonist anti-PD-1 antibody to a subject diagnosed with cancer.

[0046] The invention also provides a method of treating an immune condition comprising providing an antagonist anti-PD1 antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 for administration to a subject diagnosed with an immune condition at a dosage of about 80 mg to about 1000 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks, and administering the antagonist anti-PD-1 antibody to a subject diagnosed with cancer.

[0047] In some embodiments, the immune condition is cancer.

[0048] In some embodiments, the immune condition is a viral infection, a persistent viral infection, inflammation, an inflammatory disorder, or an autoimmune disorder or disease.

[0049] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks at a dosage of about 80 mg, about 160 mg, about 240 mg, about 320 mg, about 400 mg, about 480 mg, about 560 mg, about 720 mg, about 800 mg, about 880 mg, or about 960 mg.

[0050] The present invention also provides a method of treating cancer, comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg.

[0051] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is administered once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks.

[0052] The invention also provides a method of treating an immune condition, comprising administering to a subject diagnosed with an immune condition an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg.

[0053] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is administered once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks.

[0054] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 240 mg once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks.

[0055] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 240 mg once every two weeks.

[0056] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 240 mg once every three weeks.

[0057] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 240 mg once every four weeks.

[0058] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 240 mg once every five weeks.

[0059] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is administered at a dosage of about 240 mg once every six weeks.

[0060] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 480 mg once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks.

[0061] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 480 mg once every two weeks.

[0062] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 480 mg once every three weeks.

[0063] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 480 mg once every four weeks.

[0064] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 480 mg once every five weeks.

[0065] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is administered at a dosage of about 480 mg once every six weeks.

[0066] Cancer diagnosis and staging is performed by oncologists using established diagnostic criteria.

[0067] In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is an advanced solid tumor. "Advanced solid tumor" refers to a metastatic, unresectable, stage III, or stage IV solid tumor.

[0068] In some embodiments, the cancer is lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, stomach cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, bladder cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell cancer. lung cancer, SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, liver cancer, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, large diffuse B-cell cell lymphoma lymphoma (DLBLC), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland carcinoma, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof.

[0069] In some embodiments, the cancer is selected from the group consisting of thymic carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, bladder cancer, renal cancer, gastric cancer, esophageal cancer, or colorectal cancer (CRC).

[0070] In some embodiments, the cancer is lung cancer.

[0071] In some embodiments, the cancer is NSCLC.

[0072] In some embodiments, the cancer is melanoma.

[0073] In some embodiments, the cancer is head and neck cancer.

[0074] In some embodiments, the cancer is bladder cancer.

[0075] In some embodiments, the cancer is a gastrointestinal cancer.

[0076] In some embodiments, the cancer is gastric cancer.

[0077] In some embodiments, the cancer is gastroesophageal junction cancer.

[0078] In some embodiments, the cancer is esophageal cancer.

[0079] In some embodiments, the cancer is liver cancer.

[0080] In some embodiments, the cancer is CRC.

[0081] In some embodiments, the cancer is colon cancer.

[0082] In some embodiments, the cancer is gallbladder cancer.

[0083] In some embodiments, the cancer is biliary tract cancer.

[0084] In some embodiments, the cancer is ovarian cancer.

[0085] In some embodiments, the cancer is fallopian tube cancer.

[0086] In some embodiments, the cancer is cervical cancer.

[0087] In some embodiments, the cancer is peritoneal cancer.

[0088] In some embodiments, the cancer is endometrial cancer.

[0089] In some embodiments, the cancer is SCLC.

[0090] In some embodiments, the cancer is breast cancer.

[0091] In some embodiments, the cancer is pancreatic cancer.

[0092] In some embodiments, the cancer is renal cell carcinoma.

[0093] In some embodiments, the cancer is Merkel cell carcinoma.

[0094] In some embodiments, the cancer is PMBCL.

[0095] In some embodiments, the cancer is Hodgkin's lymphoma.

[0096] In some embodiments, the cancer is non-Hodgkin's lymphoma.

[0097] In some embodiments, the cancer is DLBLC.

[0098] In some embodiments, the cancer is multiple myeloma.

[0099] In some embodiments, the cancer is glioblastoma.

[0100] In some embodiments, the cancer is urothelial carcinoma.

[0101] In some embodiments, the cancer is salivary gland cancer.

[0102] In some embodiments, the cancer is mesothelioma.

[0103] In some embodiments, the cancer is anal cancer.

[0104] In some embodiments, the cancer is prostate cancer.

[0105] In some embodiments, the cancer is an adenocarcinoma.

[0106] In some embodiments, the cancer is metastatic prostate cancer.

[0107] In some embodiments, the prostate cancer has metastasized to the rectum, lymph nodes, or bone, or any combination thereof.

[0108] In some embodiments, the prostate cancer is recurrent or refractory prostate cancer.

[0109] In some embodiments, the prostate cancer is castration-resistant prostate cancer.

[0110] In some embodiments, the prostate cancer is sensitive to androgen deprivation therapy.

[0111] In some embodiments, the prostate cancer is not sensitive to androgen deprivation therapy.

[0112] In some embodiments, the cancer is CSCC.

[0113] In some embodiments, the cancer is basal cell carcinoma.

[0114] In some embodiments, the cancer is a thymic carcinoma.

[0115] The invention also provides a method of treating cancer comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 at a dosage of about 80 mg to about 1000 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks, wherein the subject is PD-1 axis naive.

[0116] The invention also provides a method of treating cancer comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg, wherein the subject is PD-1 axis naive.

[0117] The invention also provides a method of treating cancer comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 at a dosage of about 80 mg to about 1000 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks, wherein the subject is PD-1 axis naive and has previously received at least one therapeutic agent for the treatment of the cancer.

[0118] The invention also provides a method of treating cancer comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg, wherein the subject has previously received at least one, two, or three or more therapeutic agents for treating the cancer.

[0119] The invention also provides a method of treating cancer comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg, wherein the subject is PD-1 axis naive and has previously received at least one, two, or three or more therapeutic agents for treating the cancer.

[0120] "PD-1 axis naive" refers to a subject who has not been treated with a PD-1, PD-L1, or PD-L2 antagonist. Exemplary PD-1, PD-L1, or PD-L2 antagonists are nivolumab (Opdivo®), pembrolizumab (Keytruda®), cemiplimab (Libtayo®), sintilimab, tislelizumab, tripolibamab durvalumab (Imfinzi®), atezolizumab (Tecentriq®), avelumab (Bavencio®), or envafolimab, or any other PD-1, PD-L1, or PD-L2 antagonist. Additional such antagonists are known, including, for example, those listed on the Citeline PharmaIntelligence website.

[0121] In some embodiments, the cancer is PD-L1 positive.

[0122] In some embodiments, the cancer is PD-L1 high.

[0123] In some embodiments, the expression of PD-L1 in the cancer is not determined.

[0124] "PD-L1 positive" refers to a tumor in which at least about 1% of cells in a sample obtained from the tumor consisting of tumor cells and tumor-infiltrating inflammatory cells (such as a paraffin-embedded, formalin-fixed tumor tissue sample) stain positive for PD-L1 surface expression.

[0125] "PD-L1 high" refers to a tumor in which at least about 50% of the tumor cells or tumor-infiltrating inflammatory cells in a sample obtained from the tumor (such as a paraffin-embedded formalin-fixed tumor tissue sample) stain positive for PD-L1 surface expression. For example, commercially available kits from Ventana, DAKO, or PharmDx can be used to assess PD-L1 positive or PD-L1 high status. In these assays, PD-L1 expression on tumor cell membranes is assessed using anti-PD-L1 antibodies such as 28-8, 22C3, SP142, SP263, and 73-10, and a Tumor Proportion Score (TPS), which indicates the percentage of PD-L1 positive tumor cells, is calculated.

[0126] "Cancer where PD-L1 expression has not been determined" refers to a tumor where PD-L1 surface expression has not been assessed.

[0127] In some embodiments, the cancer expresses mutant BRAF.

[0128] In some embodiments, the mutant BRAF comprises a V600E mutation.

[0129] In some embodiments, the cancer expresses wild-type BRAF.

[0130] In some embodiments, mutant BRAF comprises one or more mutations selected from the group consisting of V600E, V600L, R462I, 1463 S, G464E, G464R, G464V, G466A, G469A, N581 S, E586K, F595L, L597Q, L597R, L597S, L597V, A598V, T599E, V600R, K601E, S602D, and A728V, and any combination thereof (see, e.g., WO 2018 / 213302).

[0131] Mitogen-activated protein kinase (MAPK) or RAS / RAF / MEK / ERK signaling participates in several cell signaling pathways involved in the control of proliferation, differentiation, and apoptosis. Activating mutations in the serine-threonine kinase BRAF gene are the most frequent genetic alteration in melanoma, with BRAF mutations observed in approximately 50% of cutaneous melanoma cases and approximately 10-20% of mucosal melanoma cases (MacKiewicz and Mackiewicz, Contem Oncol 22:68-72, 2018). Treatment of patients carrying BRAF mutations with BRAF inhibitors (e.g., vemurafenib, dabrafenib, and encorafenib) is associated with the acquisition of resistance to the treatment, therefore, MEK inhibitors such as cobimetinib, trametinib, or binimetinib can be combined into the treatment regimen. MEK inhibitors have also been tested as monotherapy in BRAF-mutated subjects.

[0132] BRAF status can be assessed from a tumor biopsy sample using known methods, such as, for example, sequencing.

[0133] In some embodiments, the subject has previously received or is ineligible for at least one therapeutic agent to treat the cancer.

[0134] In some embodiments, the subject has previously received one, two, or more therapeutic agents to treat cancer.

[0135] Therapies are known for treating various cancers and include surgery, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, targeted therapy, or any combination thereof.

[0136] Therapeutic agents for treating lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), include methotrexate, paclitaxel (ABRAXANE®), afatinib (GILOTRIF®), everolimus (Afinitor®), alectinib (ALECENSA®), pemetrexed disodium (ALIMTA®), bevacizumab (AVASTIN®), carboplatin, ceritinib (ZYKADIA®), crizotinib (XALKORI®), ramucirumab (CYRAMZA®), docetaxel, everolimus (AFINITOR®), alectinib (ALECENSA®), pemetrexed disodium (ALIMTA®), bevacizumab (AVASTIN®), carboplatin, ceritinib (ZYKADIA®), crizotinib (XALKORI®), ramucirumab (CYRAMZA®), docetaxel, everolimus (AFINITOR®), TOR®), gefitinib (IRESSA®), gemcitabine hydrochloride (GMEZAR®), pembrolizumab (KEYTRUDA®), mechlorethamine hydrochloride (MUSTARGEN®), vinorelbine tartrate (NAVELBINE®), necitumumab (PORTRAZZA®), nivolumab (OPDIVO®), carboplatin, pemetrexed disodium, ramucirumab (CYRAMZA®), osimertinib (TAGRISSO®), anti-CTLA4 antibodies, BRAF / MEK inhibitors, or interferon alpha. An exemplary anti-CTLA4 antibody is ipilimumab (YERVOY®). Exemplary BRAF / MEK inhibitors are vemurafenib (ZELBORAF®), dabrafenib, encorafenib, cobimetinib (COTELLIC®), trametinib (MEKINIST®), and binimetinib.

[0137] Therapeutic agents for treating melanoma include aldesleukin, cobimetinib (COTELLIC®), dabrafenib (TAFINLAR®), dacarbazine (DTIC-Dome®), talimogene laherparepvec (IMLYGIC®), ipilimumab (YERVOY®), pembrolizumab (KEYTRUDA®), trametinib (MEKINIST®), nivolumab (OPDIVO®), pegylated interferon alfa-2b (PEG-INTRON®, SYLATRON®), recombinant interferon alfa-2b, and vemurafenib (ZELBORAF®).

[0138] Therapies for treating bladder cancer include surgery, chemotherapy (such as cisplatin, gemcitabine, carboplatin, methotrexate, vinblastine, doxorubicin, or any combination thereof), immunotherapy (such as attenuated bacterium bacillus Calmette-Guerin (BCG), interferon, atezolizumab (TECENTRIQ®), nivolumab (OPDIVO®), durvalumab (IMFINZI®), avelumab (BAVENCIO®), or pembrolizumab (KEYTRUDA®), or radiation therapy. Therapeutic agents for treating kidney cancer include everolimus (AFINITOR®), aldesleukin, bevacizumab (AVASTIN®), axitinib (I NLYTA®), cabozantinib-S-malate (CABOMETYX®), aldesleukin (PROLEUKIN®), lenvatinib mesylate (LenVIMA®), sorafenib tosylate (NeXAVAR®), nivolumab (OPDIVO®), pazopanib hydrochloride, sorafenib tosylate, sunitinib (SUTENT®), temsirolimus (TORISEL®), and pazopanib hydrochloride (VOTRIENT®).

[0139] Therapies for treating gastric cancer include surgery or chemotherapy (such as 5-fluorouracil or capecitabine, irinotecan, docetaxel or paclitaxel, or any combination thereof). Therapies for treating esophageal cancer include surgery, endoscopic therapy, radiation therapy, chemotherapy, or targeted immunotherapy.

[0140] Therapeutic agents for treating colorectal cancer (CRC) include the chemotherapy regimen of 5-fluorouracil and leucovorin, capecitabine (XELODA®), irinotecan (CAMPTOSAR®), cetuximab (ERBITUX®), panitumumab (VECTIBIX®), pegorafenib (STIVARGA®), trifluridine and tipiracil (LONSURF®), the chemotherapy regimen of FOLFOX: leucovorin, 5-fluorouracil, and oxaliplatin (ELOXATIN®), FOLFIRI: leucovorin, 5-fluorouracil, and irinotecan (CAMPTOSAR®), and the chemotherapy regimen of 5-fluorouracil and leucovorin (CAMPTOSAR®). chemotherapy regimen of VEGF-targeted VEGF-associated ovarian tumors (VEGF-AR®), CapeOX: a chemotherapy regimen of capecitabine (XELODA®) and oxaliplatin (ELOXATIN®), FOLFOXIRI: a chemotherapy regimen of leucovorin, 5-fluorouracil, oxaliplatin (ELOXATIN®), and irinotecan (CAMPTOSAR®), or any of the above individual agents or chemotherapy regimens in combination with each other or in combination with a VEGF-targeted drug such as bevacizumab (AVASTIN®), ziv-aflibercept (ZALTRAP®), or ramucirumab (CYRAMZA®).

[0141] Therapies for treating thymic carcinoma include surgery, radiation therapy, chemotherapy (such as carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, ifosfamide, octreotide, paclitaxel, or pemetrexed, or any combination thereof), or hormone therapy (such as corticosteroids).

[0142] Radiation therapy includes external beam radiation therapy, intensity modulated radiation therapy (IMRT), focused radiation therapy, and any form of radiosurgery including Gamma Knife, Cyberlaiife, Linac, and interstitial radiation (e.g., radioactive seed implants, GliaSite balloons) and / or involving surgery.

[0143] Focused radiation methods that may be used include stereotactic radiosurgery, fractionated stereotactic radiosurgery, and intensity-modulated radiation therapy (IMRT). It is clear that in stereotactic radiosurgery, radiation is delivered precisely to the tumor tissue while avoiding the surrounding non-tumor normal tissue. The dose of radiation applied by stereotactic radiosurgery can typically vary from 1 Gy to about 30 Gy, with intermediate ranges including doses of 1 to 5, 10, 15, 20, 25, and up to 30 Gy. Thanks to the non-invasive fixation device, stereotactic radiation does not have to be delivered in a single treatment. The treatment plan can be reliably reproduced from day to day, thereby allowing multiple fractionated radiation doses to be delivered. When used to treat tumors over time, radiosurgery is called "fractionated stereotactic radiosurgery" or FSR (fractionated stereotactic radiosurgery). In contrast, stereotactic radiosurgery refers to treatment in a single session. Fractionated stereotactic radiosurgery can provide a high treatable ratio, i.e., a high proportion of tumor cells killed and a low impact on normal tissue. Tumor and normal tissue respond differently to a single high dose of radiation and multiple low doses of radiation. A single high dose of radiation can kill more normal tissue than multiple low doses of radiation. Thus, multiple low doses of radiation can kill more tumor cells while sparing normal tissue. The radiation dose applied by fractionated stereotactic radiosurgery can vary from 1 Gy to about 50 Gy, including intermediate ranges including, for example, 1-5, 10, 15, 20, 25, 30, 40, hypofractionated doses up to 50 Gy. Intensity modulated radiation therapy (IMRT) can also be used.IMRT is an improved form of three-dimensional conformal radiation therapy (3DCRT), which uses a computer-controlled linear accelerator to deliver precise radiation doses to malignant tumors or specific sites within tumors, and a multileaf collimator (MLC) to shape the contour of each radiation beam to match the contour of the target from the beam's eye view (BEV), thereby generating multiple beams. In IMRT, the intensity of the radiation beam is modulated into multiple small doses, allowing the radiation dose to be more precisely matched to the three-dimensional (3-D) shape of the tumor. Thus, IMRT allows higher radiation doses to be focused on areas within the tumor while minimizing the dose to surrounding normal and critical structures. IMRT improves the ability to conform the treatment volume to the concave shape of the tumor, for example, when the tumor covers vulnerable structures such as the spinal cord, major organs, or blood vessels. Radiation sources suitable for use as cell conditioners include both solids and liquids.

[0144] In some embodiments, the one, two, or more prior therapeutic agents for treating cancer are an anti-CTLA4 antibody, ipilimumab (YERVOY®), a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof.

[0145] "BRAF / MEK inhibitor" refers to a molecule, such as a small molecule, that inhibits at least one biological activity mediated by BRAF and / or MEK. Inhibition can be at least about 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% greater than in the absence of the inhibitor (e.g., a negative control), or when the inhibition is statistically significant when compared to a control. Exemplary biological activities mediated by BRAF and / or MEK are protein phosphorylation, cell proliferation, cell survival, and apoptosis, and can be measured using standard methods.

[0146] Exemplary BRAF inhibitors are vemurafenib (ZELBORAF®), pazopanib, dabrafenib, and encorafenib.

[0147] Exemplary MEK inhibitors are cobimetinib (COTELLIC®), trametinib (MEKINIST®), and binimetinib.

[0148] In some embodiments, the subject is resistant, refractory, or resistant and refractory to one, two, three or more previous therapeutic agents, or any combination thereof, for treating cancer.

[0149] In some embodiments, the subject is resistant, refractory, or resistant and refractory to an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon-alpha, or any combination thereof.

[0150] A variety of qualitative and / or quantitative methods can be used to determine disease recurrence or refractory status. Symptoms that may be associated with recurrence or resistance include, for example, a decline or plateau in a patient's health status, a return or worsening of various symptoms associated with solid tumors, and / or the spread of cancerous cells from one location to other organs, tissues, or cells within the body.

[0151] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof and one or more pharma- ceutically acceptable excipients.

[0152] "Pharmaceutically acceptable excipient" refers to physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, e.g., salts, buffers, antioxidants, sugars, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifying agents, or combinations thereof.

[0153] Exemplary buffers that can be used are acetate, citrate, formate, succinate, phosphate, carbonate, malate, aspartate, histidine, borate, Tris buffer, HEPPSO and HEPES.

[0154] Exemplary antioxidants that may be used are ascorbic acid, methionine, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, lecithin, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, and tartaric acid.

[0155] Exemplary amino acids that can be used are histidine, isoleucine, methionine, glycine, arginine, lysine, L-leucine, trileucine, alanine, glutamic acid, L-threonine, and 2-phenylamine.

[0156] Exemplary surfactants that may be used are polysorbates (e.g., polysorbate-20 or polysorbate-80); poloxamers (e.g., poloxamer 188); triton; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl- or disodium methyl oleyl-taurate; and the MONAQUA® series (Mona Industries, Inc. (Paterson, NJ), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (eg, PLURONICS™, PF68, etc.).

[0157] Exemplary preservatives that may be used are phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrate, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkyl parabens (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal or mixtures thereof.

[0158] Exemplary sugars that may be used are monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, non-reducing sugars, such as glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, dextran, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, melibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, or isomaltulose.

[0159] Exemplary salts that can be used are acid addition salts and base addition salts. Acid addition salts include those derived from non-toxic inorganic acids, such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid, and the like, and from non-toxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, and from non-toxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like. An exemplary salt is sodium chloride.

[0160] The amount of pharma- ceutically acceptable carrier(s) in a pharmaceutical composition can be empirically determined based on the activity of the carrier(s) and the desired properties of the formulation, e.g., stability and / or minimal oxidation.

[0161] In some embodiments, the pharmaceutical composition comprises histidine.

[0162] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 1 mM to about 50 mM.

[0163] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 5 mM to about 50 mM.

[0164] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 5 mM to about 30 mM.

[0165] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 5 mM to about 20 mM.

[0166] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 5 mM to about 15 mM.

[0167] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 5 mM to about 10 mM.

[0168] In some embodiments, the pharmaceutical composition comprises about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about and about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM, about 45 mM, about 46 mM, about 47 mM, about 48 mM, about 49 mM, or about 50 mM of histidine.

[0169] In some embodiments, the pharmaceutical composition comprises histidine at a concentration of about 10 mM.

[0170] In some embodiments, the pharmaceutical composition comprises sucrose.

[0171] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 1% (w / v) to about 20% (w / v).

[0172] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 2% (w / v) to about 18% (w / v).

[0173] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 4% (w / v) to about 16% (w / v).

[0174] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 6% (w / v) to about 14% (w / v).

[0175] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 6% (w / v) to about 12% (w / v).

[0176] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 6% (w / v) to about 10% (w / v).

[0177] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 1% (w / v), about 2% (w / v), about 3% (w / v), about 4% (w / v), about 5% (w / v), about 6% (w / v), about 7% (w / v), about 8% (w / v), about 9% (w / v), about 10% (w / v), about 11% (w / v), about 12% (w / v), about 13% (w / v), about 14% (w / v), about 15% (w / v), about 16% (w / v), about 17% (w / v), about 18% (w / v), about 19% (w / v), or about 20% (w / v).

[0178] In some embodiments, the pharmaceutical composition comprises sucrose at a concentration of about 8% (w / v).

[0179] In some embodiments, the pharmaceutical composition comprises polysorbate-20.

[0180] In some embodiments, the pharmaceutical composition comprises polysorbate-20 (PS-20) at a concentration of about 0.01% (w / v) to about 0.1% (w / v).

[0181] In some embodiments, the pharmaceutical composition comprises polysorbate-20 (PS-20) at a concentration of about 0.01% (w / v) to about 0.08% (w / v).

[0182] In some embodiments, the pharmaceutical composition comprises polysorbate-20 (PS-20) at a concentration of about 0.02% (w / v) to about 0.06% (w / v).

[0183] In some embodiments, the pharmaceutical composition comprises polysorbate-20 (PS-20) at a concentration of about 0.01% (w / v), about 0.02% (w / v), about 0.03% (w / v), about 0.04% (w / v), about 0.05% (w / v), about 0.06% (w / v), about 0.07% (w / v), about 0.08% (w / v), about 0.09% (w / v), or about 0.1% (w / v).

[0184] In some embodiments, the pharmaceutical composition comprises polysorbate-20 (PS-20) at a concentration of about 0.04% (w / v).

[0185] In some embodiments, the pharmaceutical composition comprises EDTA.

[0186] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 1 μg / ml to about 50 μg / ml.

[0187] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 5 μg / ml to about 50 μg / ml.

[0188] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 5 μg / ml to about 30 μg / ml.

[0189] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 5 μg / ml to about 20 μg / ml.

[0190] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 5 μg / ml to about 15 μg / ml.

[0191] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 5 μg / ml to about 10 μg / ml.

[0192] In some embodiments, the pharmaceutical composition comprises about 1 μg / ml, about 2 μg / ml, about 3 μg / ml, about 4 μg / ml, about 5 μg / ml, about 6 μg / ml, about 7 μg / ml, about 8 μg / ml, about 9 μg / ml, about 10 μg / ml, about 11 μg / ml, about 12 μg / ml, about 13 μg / ml, about 14 μg / ml, about 15 μg / ml, about 16 μg / ml, about 17 μg / ml, about 18 μg / ml, about 19 μg / ml, about 20 μg / ml, about 21 μg / ml, about 22 μg / ml, about 23 μg / ml, about 24 μg / ml, about 25 μg / ml, about 26 μg / ml, about 27 μg / ml, about 28 μg / ml, about 29 μg / ml, about 30 μg / ml, about 31 μg / ml, about 32 μg / ml, about 33 μg / ml, about 34 μg / ml, about 35 μg / ml, about 36 μg / ml, about 37 μg / ml, about 38 μg / ml, about 39 μg / ml, about 40 μg / ml, about 41 μg / ml, about 42 μg / ml, about 43 μg / ml, about 44 μg / ml, about 45 μg / ml, about 46 μg / ml, about 47 μg / ml, about 48 μg / ml, about 49 μg / ml, or about 50 μg / ml of EDTA.

[0193] In some embodiments, the pharmaceutical composition comprises EDTA at a concentration of about 20 μg / ml.

[0194] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, histidine, sucrose, polysorbate-20, and EDTA.

[0195] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0196] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0197] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration in a pharmaceutical composition comprising about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0198] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is provided for administration as a lyophilized formulation comprising about 90 mg to about 240 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients.

[0199] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is provided for administration as a lyophilized formulation comprising about 90 mg of the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients.

[0200] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is provided for administration as a lyophilized formulation comprising about 240 mg of the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients.

[0201] In some embodiments, the lyophilized formulation, upon reconstitution, contains about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0202] In some embodiments, the pharmaceutical composition is a liquid.

[0203] In some embodiments, the pharmaceutical composition is a frozen liquid.

[0204] In some embodiments, the pharmaceutical composition is a lyophilized powder.

[0205] In some embodiments, the pharmaceutical composition is provided in a volume of about 1 ml to about 20 ml.

[0206] In some embodiments, the pharmaceutical composition is provided in a volume of about 1 ml, about 2 ml, about 3 ml, about 4 ml, about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, about 10 ml, about 11 ml, about 12 ml, about 13 ml, about 14 ml, about 15 ml, about 16 ml, about 17 ml, about 18 ml, about 19 ml, or about 20 ml.

[0207] In some embodiments, the pharmaceutical composition is provided or reconstituted in a volume of about 3 ml.

[0208] In some embodiments, the pharmaceutical composition is provided or reconstituted in a volume of about 3.3 ml.

[0209] In some embodiments, the pharmaceutical composition is provided or reconstituted in a volume of about 8 ml.

[0210] In some embodiments, the pharmaceutical composition is provided or reconstituted in a volume of about 8.6 ml.

[0211] In some embodiments, the pharmaceutical composition is provided or reconstituted in a volume of about 8.8 ml.

[0212] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5, in a volume of about 3.3 ml.

[0213] In some embodiments, the antagonist anti-PD-1 antibody is cetrelimab, an IgG4 / κ antibody characterized by the following amino acid sequences: HCDR1 of SEQ ID NO:1, HCDR2 of SEQ ID NO:2, HCDR3 of SEQ ID NO:3, LCDR1 of SEQ ID NO:4, LCDR2 of SEQ ID NO:5, LCDR6 of SEQ ID NO:6, VH of SEQ ID NO:7, VL of SEQ ID NO:8, HC of SEQ ID NO:9, and LC of SEQ ID NO:10.

[0214] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration as a lyophilized formulation that, when reconstituted to about 3.3 ml, contains about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 90 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5), and one or more pharma- ceutically acceptable excipients.

[0215] In some embodiments, the antagonist anti-PD-1 antibody is cetrelimab.

[0216] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered or provided for administration as a lyophilized formulation that, when reconstituted to about 8.6 ml, contains about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 240 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5), and one or more pharma- ceutically acceptable excipients.

[0217] In some embodiments, the antagonist anti-PD-1 antibody is cetrelimab.

[0218] "Lyophilization," "lyophilized," and "freeze-dried" refer to a process in which the material to be dried is first frozen and then the ice or freezing solvent is removed by sublimation in a vacuum environment. Excipients may be included in the pre-lyophilized formulation to enhance the stability of the lyophilized product upon storage.

[0219] "Reconstitute", "reconstituted" or "reconstitution" refers to dissolving a lyophilized formulation in a diluent such that the proteins in the lyophilized formulation are dispersed in the reconstituted formulation. The reconstituted formulation is suitable for administration, e.g., parenteral administration, and may optionally be suitable for subcutaneous administration. In some embodiments, the diluent is sterile water for injection (sWFI).

[0220] A "pharmaceutical composition," "pharmaceutical formulation," or "formulation" refers to a combination of an active ingredient (e.g., an anti-PD-1 antibody) with one or more excipients in either liquid or solid (e.g., lyophilized) form.

[0221] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered by intravenous infusion.

[0222] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is diluted to a volume of about 100 ml to 1000 ml prior to administration.

[0223] In some embodiments, the intravenous infusion period is from about 20 minutes to about 80 minutes.

[0224] In some embodiments, the intravenous infusion period is about 20, about 30, about 40, about 50, about 60, about 70, or about 80 minutes.

[0225] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is administered by one or more subcutaneous injections.

[0226] The invention also provides a method of treating cancer comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody, or antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 at a dosage of about 80 mg to about 1000 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks, wherein the subject is PD-1 axis naive, has previously received and / or is ineligible for at least one therapeutic agent for the treatment of cancer, or any combination thereof.

[0227] In some embodiments, the method achieves an overall response rate (ORR) of at least 15% in subjects diagnosed with cancer. ORR is defined as the percentage of subjects achieving a partial response (PR) or a complete response (CR). ORR may be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or irRC in selected subjects with advanced solid tumors (irRC=-IRRC=Immune Related Response Criteria from Wolchok et al. (2009) Clin Cancer Res 15:7412-20).

[0228] In some embodiments, an ORR of at least about 15% is achieved after a median treatment period of about 1.5 months or more.

[0229] In some embodiments, an ORR of at least about 15% is achieved after a median treatment period of about 1 month or more, about 2 months or more, about 3 months or more, about 4 months or more, about 5 months or more, about 6 months or more, about 7 months or more, about 8 months or more, about 9 months or more, about 10 months or more, about 11 months or more, or about 12 months or more.

[0230] In some embodiments, the method achieves an ORR of at least about 19% in subjects diagnosed with cancer.

[0231] In some embodiments, the cancer is NSCLC.

[0232] In some embodiments, the methods achieve an ORR of at least about 30% in subjects diagnosed with PD-L1 high NSCLC, or an ORR of at least about 25% in subjects in whom PD-L1 expression in the cancer has not been determined.

[0233] In some embodiments, the method achieves an ORR of at least about 35% in subjects diagnosed with PD-L1-high NSCLC.

[0234] In some embodiments, the cancer is melanoma.

[0235] In some embodiments, the methods achieve an ORR of at least about 25% in subjects diagnosed with melanoma.

[0236] In some embodiments, the melanoma is non-uveal melanoma.

[0237] In some embodiments, the methods achieve an ORR of at least about 30% in subjects diagnosed with non-uveal melanoma.

[0238] In some embodiments, the method achieves an ORR of at least about 35% in subjects diagnosed with MSI-H CRC.

[0239] In some embodiments, the methods achieve an ORR of at least about 35% in subjects diagnosed with dMMR CRC.

[0240] The present invention also provides a method of treating colorectal cancer (CRC), comprising administering to a subject diagnosed with CRC an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising an HCDR1 of SEQ ID NO:1, an HCDR2 of SEQ ID NO:2, an HCDR3 of SEQ ID NO:3, an LCDR1 of SEQ ID NO:4, an LCDR2 of SEQ ID NO:5, and an LCDR3 of SEQ ID NO:6, for a time sufficient to treat CRC.

[0241] The invention also provides a method of treating mismatch repair-deficient (dMMR) colorectal cancer (CRC) or high-level microsatellite instability (MSI-H) CRC comprising administering to a subject diagnosed with dMMR CRC or MSI-H CRC an antagonist anti-PD1 antibody, or antigen-binding fragment thereof, comprising an HCDR1 of SEQ ID NO:1, an HCDR2 of SEQ ID NO:2, an HCDR3 of SEQ ID NO:3, an LCDR1 of SEQ ID NO:4, an LCDR2 of SEQ ID NO:5, and an LCDR3 of SEQ ID NO:6, for a time sufficient to treat the dMMR CRC or MSI-H CRC.

[0242] Approximately 15% of colorectal cancers (CRCs) have DNA mismatch repair deficiency (dMMR), characterized by microsatellite instability (MSI) in the tumor. Tumors with dMMR / MSI typically arise from germline mutations in one of the MMR genes or somatic inactivation of the same pathway. dMMR / MSI tumors include hereditary non-polyposis colorectal cancer (HNPCC), also called Lynch syndrome and sporadic MSI-H CRC. Lynch syndrome is caused by germline mutations in the MMR genes MLH1, MSH2, MSH6, or PMS2, or epigenetic inactivation of MSH2. Sporadic MSI-H CRC is often caused by methylation of the MLH1 promoter. A subset of MSI-H tumors does not have alterations in the MMR genes themselves, but instead overexpress various miRNAs that can silence MMR genes. For example, miRNA-21 was found to be overexpressed in MSI-H CRCs, targeting MSH2 and MSH6 mRNA.

[0243] MSI-H CRC can be detected using polymerase chain reaction (PCR) of tumor tissue samples to detect the stability of microsatellite markers. A CRC is classified as MSI-H if more than 30% of the microsatellite markers with at least five markers evaluated show instability. The National Cancer Institute recommends a panel of five microsatellites for MSI screening: BAT25 and BAT26 (mononucleotide repeats), D2S123, D5S346, and D17S250 (dinucleotide repeats). dMMR can be detected using immunohistochemistry of tumor tissue. A CRC is classified as dMMR if loss of at least one MMR gene, MLH1, MSH2, MSH6, or PMS2, is detected in the tumor tissue.

[0244] In some embodiments, the CRC is stage II CRC or stage III CRC. For example, CRC staging is known using the American Joint Committee on Cancer (AJCC) TNM system and diagnosis by an oncologist.

[0245] In some embodiments, the subject diagnosed with CRC is refractory to treatment with a fluoropyrimidine, oxaliplatin, or irinotecan, or any combination thereof.

[0246] In some embodiments, the subject diagnosed with CRC has a recurrent tumor following treatment with a fluoropyrimidine, oxaliplatin, or irinotecan, or any combination thereof.

[0247] A variety of qualitative and / or quantitative methods can be used to determine disease recurrence or refractory status. Symptoms that may be associated with recurrent or refractory disease include, for example, a decline or plateau in the patient's health, a return or worsening of various symptoms associated with the tumor, and / or the spread of cancerous cells from one location to other organs, tissues, or cells within the body.

[0248] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody, or antigen-binding fragment thereof, comprising HCDR1 of SEQ ID NO:1, HCDR2 of SEQ ID NO:2, HCDR3 of SEQ ID NO:3, LCDR1 of SEQ ID NO:4, LCDR2 of SEQ ID NO:5, and LCDR3 of SEQ ID NO:6, for a time sufficient to treat the thymic carcinoma.

[0249] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8, for a time sufficient to treat the thymic carcinoma.

[0250] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO: 9 and a light chain (LC) of SEQ ID NO: 10 for a time sufficient to treat the thymic carcinoma.

[0251] The present invention also provides a method of treating thymic carcinoma, comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 80 mg to about 1000 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0252] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 80 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0253] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 160 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0254] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 240 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0255] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 320 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0256] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 400 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0257] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 480 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0258] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 560 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0259] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 720 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0260] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 800 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0261] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 880 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0262] The invention also provides a method of treating thymic carcinoma comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10 at a dosage of about 960 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0263] In some embodiments, the thymic cancer is a thymoma.

[0264] In some embodiments, the thymoma is a type A thymoma.

[0265] In some embodiments, the thymoma is a type AB thymoma.

[0266] In some embodiments, the thymoma is a type B1 thymoma.

[0267] In some embodiments, the thymoma is a type B2 thymoma.

[0268] In some embodiments, the thymoma is a type B3 thymoma.

[0269] In some embodiments, the thymic cancer is a thymic carcinoma.

[0270] In some embodiments, the thymic carcinoma is a low-grade thymic carcinoma.

[0271] In some embodiments, the thymic carcinoma is a high-grade thymic carcinoma.

[0272] In some embodiments, the thymic cancer is metastatic thymic carcinoma.

[0273] In some embodiments, the thymic carcinoma has metastasized to the lung, lymph nodes, heart, or bone.

[0274] In some embodiments, the subject has been treated with surgery, radiation therapy, chemotherapy, or hormone therapy.

[0275] In some embodiments, the subject has been treated with carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, ifosfamide, octreotide, paclitaxel, or pemetrexed, or any combination thereof.

[0276] Thymic carcinoma can be staged, for example, according to the American Society of Clinical Oncology (ASCO) staging system.

[0277] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) of SEQ ID NO:7 and a light chain variable region (VL) of SEQ ID NO:8.

[0278] In some embodiments, the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is of the IgG1, IgG2, and IgG3, or IgG4 isotype.

[0279] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is of the IgG4 isotype.

[0280] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, is of an IgG4 isotype and contains a proline at position 228, numbered according to the EU index.

[0281] In some embodiments, the antagonist anti-PD-1 antibody is the nG4m(a) allotype.

[0282] In some embodiments, the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, comprises at least one substitution in the Fc region to modulate antibody effector function or antibody half-life.

[0283] In some embodiments, the antagonist anti-PD-1 antibody comprises a heavy chain of SEQ ID NO:9 and a light chain of SEQ ID NO:10.

[0284] The invention also provides a pharmaceutical composition comprising about 10 mg / mL of an antagonist anti-PD-1 antibody comprising a HC of SEQ ID NO:9 and a LC of SEQ ID NO:10, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate 20, and about 20 μg / ml EDTA, pH 6.5.

[0285] SEQ ID NO:1 SYAIS

[0286] SEQ ID NO:2 GIIPIFDTANYAQKFQG

[0287] SEQ ID NO:3 PGLAAAYDTGSLDY

[0288] SEQ ID NO:4 RASQSVRSYLA

[0289] SEQ ID NO:5 DASNRAT

[0290] SEQ ID NO:6 QQRNYWPLT

[0291] SEQ ID NO:7 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS

[0292] SEQ ID NO:8 EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK

[0293] SEQ ID NO:9 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDY WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY GPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0294] SEQ ID NO:10 EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0295] The present invention also relates to a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5), about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); A lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; A lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or Also provided is a pharmaceutical composition comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients.

[0296] In some embodiments, the lyophilized formulation, upon reconstitution, comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0297] The present invention also relates to a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5), about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); A lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; A lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or Also provided is a drug formulation comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients.

[0298] In some embodiments, the lyophilized formulation, upon reconstitution, comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0299] In some embodiments, the lyophilized formulation is reconstituted in sterile water for injection (sWFI).

[0300] The invention also provides a drug product comprising about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5, in a volume of about 3.3 ml.

[0301] The invention also provides a drug product comprising a lyophilized formulation containing about 90 mg of cetrelimab, which when reconstituted to about 3.3 ml, contains about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA, pH 6.5.

[0302] The invention also provides a drug product comprising a lyophilized formulation containing about 240 mg of cetrelimab, which when reconstituted to about 8.6 ml, contains about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA, pH 6.5.

[0303] The present invention also provides a composition comprising about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5), for the treatment of cancer. about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); A lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; A lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or Also provided is a drug product comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients.

[0304] In some embodiments, the lyophilized formulation, upon reconstitution, comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5.

[0305] In some embodiments, the drug product is provided for the treatment of lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, liver cancer, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBLC), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland cancer, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof.

[0306] In some embodiments, drug products are provided for the treatment of NSCLC, melanoma, bladder cancer, renal cell carcinoma, SLCL, CRC, gastric cancer, prostate cancer, or esophageal cancer.

[0307] In some embodiments, a drug product is provided for the treatment of PD-L1 high NSCLC.

[0308] In some embodiments, a drug product is provided for the treatment of MSI-H CRC or dMMR CRC.

[0309] In some embodiments, a drug product is provided for the treatment of non-uveal melanoma.

[0310] In some embodiments, the drug product comprises: Once every two weeks, at a dosage of approximately 240 mg, Once every 4 weeks at a dosage of approximately 480 mg, or An initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after the initial dose, and then about 480 mg every 4 weeks thereafter; or An initial dose of about 240 mg is administered, followed by a second dose of about 480 mg six weeks after the initial dose, and then about 240 mg every two weeks.

[0311] In some embodiments, the drug product is administered intravenously or subcutaneously, or a combination thereof.

[0312] Generation of antibodies for use in the methods of the invention Antagonist anti-PD-1 antibodies or antigen-binding fragments thereof used in the methods of the invention can be produced using a variety of techniques. For example, monoclonal antibodies can be produced using the hybridoma method of Kohler and Milstein. In the hybridoma method, mice or other host animals (e.g., hamsters, rats, or monkeys) are immunized with human and / or cynomolgus PD-1 antigens, such as the extracellular domain of PD-1, and spleen cells of the immunized animals are then fused with myeloma cells to form hybridoma cells using standard methods. Colonies arising from a single immortalized hybridoma cell may be screened for production of antibodies with the desired properties (e.g., binding specificity, cross-reactivity or lack thereof, affinity for antigen, and functionality such as antagonist activity).

[0313] Exemplary humanization techniques involving the selection of human acceptor frameworks include CDR grafting (U.S. Pat. No. 5,225,539), SDR grafting (U.S. Pat. No. 6,818,749), resurfacing (Padlan, (1991) Mol Immunol 28:489-499), resurfacing of specificity determining residues (U.S. Pat. App. Pub. No. 2010 / 0261620), human framework adaptation (U.S. Pat. No. 8,748,356), or superhumanization (U.S. Pat. No. 7,709,226). These methods involve grafting the CDRs or a subset of CDR residues of a parent antibody onto a human framework that may be selected based on overall homology to the parent framework, based on similarity in CDR length or identity of canonical structure, or a combination thereof.

[0314] Humanized antibodies may be further optimized to improve their selectivity or affinity for the desired antigen by incorporating altered framework support residues that preserve binding affinity (backmutations) or by introducing mutations in any of the CDRs, for example to improve the affinity of the antibody, by techniques such as those described in WO 1090 / 007861 and WO 1992 / 22653.

[0315] Transgenic animals, such as mice or rats, carrying human immunoglobulin (Ig) loci in their genome can be used to generate antibodies against PD-1, as described, for example, in U.S. Patent No. 6,150,584, WO 1999 / 45962, WO 2002 / 066630, WO 2002 / 43478, WO 2002 / 043478, and WO 1990 / 04036. The endogenous immunoglobulin loci of such animals may be disrupted or deleted, and at least one complete or partial human immunoglobulin locus may be inserted into the animal's genome using homologous or non-homologous recombination, using a transchromosome, or using a minigene. Companies such as Regeneron (http: / / _www_regeneron_com), Harbour Antibodies (http: / / _www_harbourantibodies_com), Open Monoclonal Technology, Inc. (OMT) (http: / / _www_omtinc_net), KyMab (http: / / _www_kymab_com), Trianni (http: / / _www.trianni_com), and Ablexis (http: / / _www_ablexis_com) may be working to provide human antibodies targeted to selected antigens using the above technology.

[0316] Antibodies can be selected from phage display libraries, where phages have been engineered to express human immunoglobulins or portions thereof, such as, for example, Fabs, single chain antibodies (scFvs), or unpaired or paired antibody variable regions. Antibodies of the invention can be isolated from phage display libraries expressing antibody heavy and light chain variable regions as fusion proteins with bacteriophage pIX coat protein, e.g., as described in Shi et al., (2010) J Mol Biol 397:385-96 and WO 09 / 085462). Libraries can be screened for phage binding to human and / or cynomolgus PD-1, and the resulting positive clones can be further characterized, and Fabs can be isolated from lysates of clones and expressed as full-length IgG.

[0317] The CDRs of an antibody can be grafted onto any human framework and the resulting antibody can be tested for functionality. For example, the antibody JNJ-63723283 contains frameworks derived from human germline genes IGHV1-69 and IGKV3-11. Alternatively, the JNJ-63723283 HCDRs can be grafted onto other IGHV1 germline gene subgroup frameworks and the LCDRs can be grafted onto other IGKV3 germline gene subgroup frameworks and the resulting antibody can be tested for the desired functionality. Human germline gene sequences are well known and can be retrieved, for example, from the ImMunoGeneTics Information System®.

[0318] Preparation of immunogenic antigens and generation of monoclonal antibodies can be carried out using any suitable technique, including recombinant protein production. Immunogenic antigens may be administered to an animal in the form of purified proteins or protein mixtures including whole cells or cell or tissue extracts, or antigens may be formed de novo in the animal from nucleic acids encoding the antigen or a portion thereof.

[0319] Methods for producing antibodies Methods for producing antibodies on a large scale are known. Antibodies can be produced, for example, in cultured CHO cells using known methods. Antibodies can be isolated and / or purified from the culture medium by removing solids by centrifugation or filtration as a first step in the purification process. Antibodies can be further purified by standard methods including chromatography (e.g., ion exchange, affinity, size exclusion, and hydroxyapatite chromatography), gel filtration, centrifugation, or differential solubility, ethanol precipitation, or any other available technique for purification of antibodies. Protease inhibitors such as phenyl methyl sulfonyl fluoride (PMSF), leupeptin, pepstatin, or aprotinin can be added at any or all stages to reduce or eliminate degradation of the antibody during the purification process. Those skilled in the art will understand that the exact purification technique will vary depending on the characteristics of the polypeptide or protein being purified, the characteristics of the cells in which the polypeptide or protein is expressed, and the composition of the medium in which the cells are grown.

[0320] Further embodiments of the present invention Certain further embodiments of the invention, in accordance with the disclosure elsewhere herein, are set forth below, and features of the embodiments of the invention described above as relating to the invention disclosed herein also pertain to each and every one of these numbered further embodiments. 1) An antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 for use in treating a subject having cancer, wherein the antagonist anti-PD-1 antibody is administered at a dosage of about 240 mg to about 480 mg. 2) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 1, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks. 3) the antagonist anti-PD1 antibody or antigen-binding fragment thereof is a) once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks at a dosage of approximately 240 mg; b) once every two weeks at a dosage of approximately 240 mg; c) once every three weeks at a dosage of approximately 240 mg; d) once every four weeks at a dosage of approximately 240 mg; e) Once every 5 weeks at a dosage of approximately 240 mg f) once every six weeks at a dosage of approximately 240 mg; g) once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks at a dosage of approximately 480 mg; h) once every two weeks at a dosage of approximately 480 mg i) once every three weeks at a dosage of approximately 480 mg; j) once every four weeks at a dosage of approximately 480 mg k) once every 5 weeks in a dosage of approximately 480 mg; or l) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 1 or 2, administered in a dosage of about 480 mg once every 6 weeks. 4) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 1 or 2, wherein the cancer is a solid tumor. 5) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 4, wherein the solid tumor is an advanced solid tumor. 6) Cancer is lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, stomach cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, liver cancer, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, 6. The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 5, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBLC), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland carcinoma, mesothelioma, anal carcinoma, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof. 7) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 6, wherein the subject is PD-1 axis naive. 8) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 7, wherein the subject has previously received one, two, or three or more therapeutic agents for treating cancer. 9) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 8, wherein one, two, or more prior therapeutic agents for treating cancer are an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof. 10) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 9, wherein the subject is resistant, refractory, or resistant and refractory to one, two, three or more previous therapeutic agents for treating cancer, or any combination thereof. 11) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 10, wherein one, two, or more prior therapeutic agents for treating cancer are an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof. 12) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 11, wherein the cancer is PD-L1 positive. 13) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 12, wherein the cancer is PD-L1 high. 14) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 13, wherein the expression of PD-L1 in the cancer has not been determined. 15) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 14, wherein the cancer expresses mutant BRAF. 16) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 15, wherein the mutant BRAF comprises a V600E mutation. 17) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 16, wherein the cancer expresses wild-type BRAF. 18) The antagonist anti-PD1 antibody or antigen-binding fragment thereof, a) administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of an antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); b) administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml of an antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) administered or provided for administration in a pharmaceutical composition comprising about 30 mg / ml of an antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) provided for administration as a lyophilized formulation comprising about 90 mg to about 240 mg of an antagonist anti-PD-1 antibody or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients; e) provided for administration as a lyophilized formulation comprising about 90 mg of the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients; or f) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 17, provided for administration as a lyophilized formulation comprising about 240 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients. 19) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 18, wherein the lyophilized formulation of d), e), and / or f) upon reconstitution comprises about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5. 20) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 19, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered by intravenous infusion. 21) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 20, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered by subcutaneous injection. 22) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 21, wherein the method achieves an overall response rate (ORR) of at least about 15% in a group of subjects diagnosed with cancer. 23) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 22, wherein an ORR of at least about 15% is achieved after a median treatment period of about 1.5 months or more. 24) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 22 or 23, wherein the method achieves an ORR of at least about 19% in a group of subjects diagnosed with cancer. 25) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 6, wherein the cancer is non-small cell lung cancer (NSCLC). 26) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 25, wherein the method achieves an ORR of at least about 30% in a subject group diagnosed with PD-L1 high NSCLC, or an ORR of at least about 25% in a subject group in which PD-L1 expression in the cancer has not been determined. 27) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 25 or 26, wherein the method achieves an ORR of at least about 35% in a group of subjects diagnosed with PD-L1-high NSCLC. 28) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 6, wherein the cancer is melanoma. 29) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 28, wherein the method achieves an ORR of at least about 25% in a group of subjects diagnosed with melanoma. 30) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 28 or 29, wherein the melanoma is non-uveal melanoma. 31) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 30, wherein the method achieves an ORR of at least about 30% in a group of subjects diagnosed with non-uveal melanoma. 32) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 31, wherein the CRC is microsatellite instability-high (MSI-H) CRC or mismatch repair deficient (dMMR) CRC, or a combination thereof. 33) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to embodiment 32, wherein the CRC is stage II CRC or stage III CRC. 34) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 33, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8. 35) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 34, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is of the IgG1, IgG2, IgG3, or IgG4 isotype. 36) The antagonist anti-PD1 antibody or antigen-binding fragment thereof for use according to any one of embodiments 1 to 35, wherein the antagonist anti-PD-1 antibody comprises a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 10. 37) A pharmaceutical composition comprising: a) about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A pharmaceutical composition comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. 38) The pharmaceutical composition of embodiment 37, wherein the lyophilized formulation of d), e), and / or f) upon reconstitution comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5. 39) A drug product comprising: a) about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A drug product comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. 40) The drug product of embodiment 39, wherein the lyophilized formulation of d), e), and / or f) upon reconstitution comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5. 41) A drug product for use in treating a subject having cancer, a) about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A drug product comprising a lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. 42) The drug product of embodiment 41, wherein the lyophilized formulation of d), e), and / or f) upon reconstitution comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5. 43) The drug product of embodiment 41, wherein the cancer is lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, liver cancer, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBLC), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland cancer, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof. 44) a) the NSCLC is PD-L1 high NSCLC, b) the CRC is an MSI-H CRC or a dMMR CRC, or c) The drug product of embodiment 43, wherein the melanoma is non-uveal melanoma, or any combination thereof. 45) Drug products: a) Once every two weeks at a dosage of approximately 240 mg, b) once every four weeks in a dosage of approximately 480 mg; or c) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after the initial dose, and then about 480 mg every 4 weeks thereafter; or d) The drug product of embodiment 41, wherein an initial dose of about 240 mg is administered, followed by a second dose of about 480 mg 6 weeks after the initial dose, and then about 240 mg once every two weeks. 46) The drug product of embodiment 41, wherein the drug product is administered intravenously or subcutaneously, or a combination thereof. 47) A method of treating cancer, comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody or antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dosage of about 80 mg to about 1000 mg once every 2, 3, 4, 5, or 6 weeks. 48) The method of embodiment 47, comprising providing an antagonist anti-PD1 antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6 for administration to a subject diagnosed with cancer in a dosage of about 80 mg to about 1000 mg once every 2, 3, 4, 5, or 6 weeks; and administering the antagonist anti-PD1 antibody or antigen-binding fragment thereof to the subject diagnosed with cancer. 49) The method of embodiment 48, wherein the cancer is an advanced solid tumor. 50) The method of any one of embodiments 47-49, wherein the subject has previously received or is ineligible for at least one therapeutic agent for treating cancer. 51) The method of any one of embodiments 47-50, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered at a dosage of about 80 mg, about 160 mg, about 240 mg, about 320 mg, about 400 mg, about 480 mg, about 560 mg, about 720 mg, about 800 mg, about 880 mg, or about 960 mg once every 2, 3, 4, 5, or 6 weeks. 52) The method of any one of embodiments 47-51, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered once every two weeks at a dosage of about 240 mg, or once every four weeks at a dosage of about 480 mg. 53) The method of any one of embodiments 47-52, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is provided in a pharmaceutical composition comprising about 10 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% polysorbate-20, and about 20 μg / ml EDTA (pH 6.5). 54) The method of any one of embodiments 47 to 53, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is administered by intravenous infusion. 55) The method of any one of embodiments 47 to 54, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is diluted to a volume of about 100 ml to 1000 ml prior to administration. 56) A method according to any one of embodiments 47 to 55, wherein the intravenous infusion period is from about 20 minutes to about 80 minutes. 57) The method of any one of embodiments 47 to 56, wherein the intravenous infusion period is about 20, about 30, about 40, about 50, about 60, about 70 minutes, or about 80 minutes. 58) The method of any one of embodiments 47 to 57, wherein the cancer is selected from the group consisting of thymic carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, bladder cancer, renal cancer, gastric cancer, esophageal cancer, and colorectal cancer (CRC). 59) The method of any one of embodiments 47 to 58, wherein the thymic cancer is thymoma, thymic carcinoma, or metastatic thymic cancer, or any combination thereof. 60) The method of any one of embodiments 47 to 59, wherein the thymoma is type A thymoma, type AB thymoma, type B1 thymoma, type B2 thymoma, or type B3 thymoma. 61) The method of any one of embodiments 47 to 60, wherein the thymic carcinoma is a low-grade thymic carcinoma or a high-grade thymic carcinoma. 62) The method of any one of embodiments 47 to 61, wherein the thymic carcinoma has metastasized to the lungs, lymph nodes, heart, or bone. 63) The method of any one of embodiments 47 to 62, wherein the subject is being treated with surgery, radiation therapy, chemotherapy, or hormone therapy. 64) The method of any one of embodiments 47 to 63, wherein the chemotherapy is carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, ifosfamide, octreotide, paclitaxel, or pemetrexed, or any combination thereof. 65) The method of any one of embodiments 47 to 64, wherein the CRC is microsatellite instability-high (MSI-H) CRC or mismatch repair deficient (dMMR) CRC, or a combination thereof. 66) The method of any one of embodiments 47 to 65, wherein the CRC is stage II CRC or stage III CRC. 67) The method of any one of embodiments 47-66, wherein the subject has CRC that is refractory to or recurrent after treatment with a fluoropyrimidine, oxaliplatin, or irinotecan, or any combination thereof. 68) The method of any one of embodiments 47 to 67, wherein the subject is PD-1 axis naive. 69) The method of any one of embodiments 47 to 68, wherein the subject is PD-1 axis naive and has previously received at least one therapeutic agent for treating cancer. 70) The method of any one of embodiments 47 to 69, wherein the cancer is PD-L1 positive. 71) The method of any one of embodiments 47 to 70, wherein the cancer is PD-L1 high. 72) The method of any one of embodiments 47-71, wherein the method achieves an overall response rate (ORR) of at least about 15% in a group of subjects diagnosed with cancer. 73) The method of any one of embodiments 47-72, wherein the method achieves an ORR of at least about 35% in subjects diagnosed with MSI-H CRC, an ORR of at least about 35% in subjects diagnosed with dMMR CRC, an ORR of at least about 30% in subjects diagnosed with PD-L1 high NSCLC, or an ORR of at least about 25% in subjects diagnosed with melanoma, or any combination thereof. 74) The method of any one of embodiments 47 to 73, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8. 75) The method of any one of embodiments 47 to 74, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof is an IgG1, IgG2, and IgG3, or IgG4 isotype. 76) The method of any one of embodiments 47 to 75, wherein the antagonist anti-PD-1 antibody comprises a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 10. 77) A pharmaceutical composition comprising about 10 mg / mL of an antagonist anti-PD-1 antibody comprising a heavy chain (HC) of SEQ ID NO:9 and a light chain (LC) of SEQ ID NO:10, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% polysorbate-20, and about 20 μg / ml EDTA (pH 6.5). 78) A method of treating thymic carcinoma, comprising administering to a subject diagnosed with thymic carcinoma an antagonist anti-PD1 antibody, or an antigen-binding fragment thereof, comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO:1, HCDR2 of SEQ ID NO:2, HCDR3 of SEQ ID NO:3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO:4, LCDR2 of SEQ ID NO:5, and LCDR3 of SEQ ID NO:6, for a time sufficient to treat the thymic carcinoma. 79) The method of any of embodiment 78, wherein the thymic cancer is thymoma, thymic carcinoma, or metastatic thymic cancer, or any combination thereof. 80) The method of any of embodiments 78 or 79, wherein the thymoma is type A thymoma, type AB thymoma, type B1 thymoma, type B2 thymoma, or type B3 thymoma. 81) The method of any one of embodiments 78 to 80, wherein the thymic carcinoma is a low-grade thymic carcinoma or a high-grade thymic carcinoma. 82) The method of any one of embodiments 78 to 81, wherein the thymic carcinoma has metastasized to the lungs, lymph nodes, heart, or bone. 83) The method of any one of embodiments 78 to 82, wherein the subject is being or will be treated with surgery, radiation therapy, chemotherapy, or hormonal therapy, or any combination thereof. 84) The method of any one of embodiments 78 to 83, wherein the chemotherapy is carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, ifosfamide, octreotide, paclitaxel, or pemetrexed, or any combination thereof. 85) The method of any one of embodiments 78-84, wherein the subject is PD-1 axis naive, has previously received and / or is ineligible to receive at least one therapeutic agent for treating cancer, or any combination thereof. 86) The method of any one of embodiments 78 to 85, wherein the subject is PD-1 axis naive and has previously received at least one therapeutic agent for treating cancer. 87) The method of any one of embodiments 78 to 86, wherein the cancer is PD-L1 positive. 88) The method of any one of embodiments 78 to 87, wherein the cancer is PD-L1 high. 89) The method of any one of embodiments 78-88, wherein the method achieves an overall response rate (ORR) of at least about 15% in a group of subjects diagnosed with cancer. 90) The method of any one of embodiments 78-89, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of SEQ ID NO:7 and a light chain variable region (VL) of SEQ ID NO:8. 91) The method of any one of embodiments 78 to 90, wherein the antagonist anti-PD-1 antibody is an IgG1, IgG2, and IgG3, or IgG4 isotype. 92) The method of any one of embodiments 78 to 91, wherein the antagonist anti-PD-1 antibody comprises a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 10. 93) The method of any one of embodiments 78-92, wherein the antagonist anti-PD1 antibody or antigen-binding fragment thereof is provided in a pharmaceutical composition comprising about 10 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% polysorbate-20, and about 20 μg / ml EDTA (pH 6.5).

[0321] The invention will now be described with reference to the following specific, non-limiting examples. Example 1. A First-in-Human, Open-Label, Phase 1 / 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer (NCT02908906) This is a first-in-human (FIH), Phase 1 / 2, open-label, multicenter study to establish RP2D(s) for JNJ-63723283 in Part 1 and evaluate the safety and efficacy of the RP2D(s) in Part 2. Part 1 consists of a dose escalation cohort and a pharmacokinetic / pharmacodynamic cohort. In Part 2, one or more of the RP2D(s) determined in Part 1 will be evaluated in select solid tumor types, including NSCLC, melanoma, bladder cancer, renal cancer, small cell lung cancer (SCLC), gastric / esophageal cancer, MSI-H or dMMR CRC, and thymoma (including thymic carcinoma). The overall safety of JNJ-63723283 will be evaluated by the Safety Evaluation Team (SET). Subjects will continue to receive JNJ-63723283 until disease progression, unacceptable toxicity, withdrawal of consent, or end of study.

[0322] Main purpose: To identify the recommended phase 2 dose(s) (RP2D(s)) of JNJ-63723283 (Part 1) To evaluate the antitumor activity of JNJ-63723283 at RP2D(s) in subjects with selected advanced cancers, including NSCLC, melanoma, renal cancer, bladder cancer, SCLC, gastric / esophageal cancer, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and thymoma (Part 2)

[0323] Secondary Objectives: To characterize the safety of JNJ-63723283 in subjects with advanced solid tumors To characterize the pharmacokinetics of JNJ-63723283 administered intravenously To evaluate the immunogenicity of JNJ-63723283 To evaluate the clinical activity of JNJ-63723283

[0324] Primary endpoint(s) The frequency and severity of dose-limiting toxicity (DLT) - Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in select subjects with advanced solid tumors

[0325] Secondary endpoint(s) - Safety profile of JNJ-63723283 (safety parameters include, but are not limited to, adverse events (AEs) and immune-related AEs (irAEs), vital sign measurements, clinical laboratory values, and electrocardiograms (ECGs)) Serum JNJ-63723283 pharmacokinetic parameters, including but not limited to the maximum observed serum concentration (Cmax), the area under the concentration-time curve between two defined sampling points t1 and t2 (AUCt1-t2), half-life (T1 / 2), total systemic clearance of the drug after IV administration (CL), volume of distribution at steady-state (Vss), and accumulation ratio (R). Presence of anti-JNJ-63723283 antibodies and effect on serum JNJ-63723283 concentrations ORR by Immune-Related Response Criteria (irRC), duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS) by both RECIST v.1.1 and irRC, and OS

[0326] search: To characterize the pharmacodynamics of JNJ-63723283, including quantification of JNJ-63723283 receptor occupancy on peripheral T cells and cytokine responses to ex vivo stimulation of peripheral T cells. To explore the relationship between the pharmacokinetics, pharmacodynamics, AE profile, and clinical activity of JNJ-63723283

[0327] Target population Subjects must be ≥ 18 years old and have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. All subjects have histologically or cytologically confirmed solid tumors, excluding lymphoma, that are metastatic or unresectable, and have previously received or been ineligible for standard treatment options. In addition, subjects have not previously received treatment with anti-PD-1 or anti-PD-L1 antibodies (i.e., anti-PD-1 and anti-PD-L1 naive). In part 2, subjects have one of the following selected tumor types: PD-L1 high NSCLC, bladder, gastric / esophageal, melanoma, renal, SCLC, MSI-H, or dMMR CRC.

[0328] Dosage and Administration Study drug will initially be administered via IV infusion once every 2 weeks. Dose escalation may begin with a starting dose of 80mg and continue with doses of 160mg, 240mg, 320mg, 400mg, 480mg, 560mg, 640mg, 720mg, and 800mg. Dosing schedules and infusion durations may be modified based on new safety, pharmacokinetic, and pharmacodynamic / biomarker data and as confirmed by SET. Alternative dosages and schedules (e.g., once every 3 or 4 weeks) may be explored in Part 1. One or more RP2D(s) of JNJ-63723283 may be evaluated in Part 2.

[0329] Safety assessment Safety will be assessed by physical examination, ECOG performance status, clinical laboratory tests, vital signs, electrocardiogram, AE monitoring, and concomitant medication use. Echocardiogram or multi-gated acquisition scan will be assessed at screening. Subsequent evaluations will be performed as clinically indicated. AE severity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 4).

[0330] Efficacy assessment Response to treatment will be assessed by the investigator according to RECIST v1.1 and irRC. Efficacy assessments will include: computed tomography (CT) scans and / or magnetic resonance imaging (MRI), physical examination, and other procedures as appropriate.

[0331] statistical methods The objective of Part 1 is to identify RP2D(s) in subjects with advanced solid tumors. Dose escalation is supported by a statistical model, a modified Continual Reassessment Method (mCRM) based on the Bayesian Logistic Regression Model (BLRM), using the Escalation with Overdosage Control (EWOC) principle. The total number of subjects treated depends on the number of dose levels explored and the number of subjects enrolled at each dose level. In Part 2, it is assumed that the ORR of JNJ-63723283 by RECIST v1.1 administered at the RP2D(s) is at least 15% in subjects with selected solid tumors. It is also assumed that the ORR is 35% for MSI-H / dMMR CRC, 30% for PD-L1 high NSCLC, and 25% for melanoma. The ORR for thymoma is for a hypothesis-generating study. Interim monitoring for efficacy will be conducted.

[0332] Pharmacokinetic and immunogenicity sampling rationale Serum samples will be collected and analyzed for JNJ-63723283 concentrations in Part 1 and Part 2, with estimation of basic pharmacokinetic parameters from this concentration-time data. Pharmacokinetics will be assessed against available clinical safety, pharmacokinetic, and efficacy data, as well as any effective concentration thresholds observed in non-clinical or competitive studies. Pharmacokinetic or pharmacokinetic / pharmacodynamic analysis and modeling will be used to aid in the selection of RP2D regimens for use in Part 2. Immunogenicity (i.e., ADA) will be evaluated for impact on pharmacokinetics and safety. The serum glycoform profile of JNJ-63723283 will also be characterized.

[0333] Pharmacodynamic and biomarker sampling rationale JNJ-63723283 is expected to induce phenotypic changes consistent with T cell activation in peripheral blood and tumor tissue. Pharmacodynamic evaluation is based on evaluation of activation and proliferation markers, as well as cytokine profiles of T cells in peripheral blood. Peripheral blood samples can also be used to quantify immune cell responses in ex vivo stimulation assays. PD-1 polymorphisms can affect the efficacy of anti-PD-1 antibodies, so PD-1 polymorphisms can be evaluated for possible correlation with clinical activity. JNJ-63723283 is expected to demonstrate binding to PD-1 on circulating immune cells following administration to human subjects. PD-1 receptor occupancy by JNJ-63723283 on circulating CD3+ T cells is measured using flow cytometry. Properties including dosage dependency, peak occupancy, plateau occupancy, and duration of occupancy at the plateau are evaluated as feasible.

[0334] Rationale for Part 2 PD-L1 Study Expression of PD-L1, the ligand for PD-1, correlates with enhanced clinical activity in multiple tumor types, including NSCLC cancer. In Part 2, tumor tissue for PD-L1 testing will be required for all tumor types. This is necessary to correlate clinical response with PD-L1 expression on tumor tissue.

[0335] Rationale for MSI or dMMR testing in part 2 Compared with other tumors, MSI-H and dMMR CRCs harbor a higher frequency of DNA mutations and higher levels of immune infiltration, and are therefore more amenable to PD-1 blockade therapy. Pre-screening for MSI-H or dMMR is required for the CRC group in part 2.

[0336] Dosage The recommended FIH starting dosage regimen for JNJ-63723283 is 80 mg administered as an IV infusion every 2 weeks. In addition to dosing every 2 weeks, additional dosing intervals such as every 3, 4, or 6 weeks may be explored in part 1 for further characterization of JNJ-63723283 pharmacology. The maximum dose administered is planned to be 800 mg, but may be lower or higher based on new data. Initially, it will be administered intravenously in a 60 (±10) minute infusion. If there is no response to the infusion, subsequent infusions may be administered intravenously over 30 (-5 / +10) minutes. Longer infusion times may occur if the infusion needs to be paused or slowed due to safety concerns. It is also not recommended to administer ≥ 100 mL of diluted drug product faster than 30 (-5 / +10) minutes or ≥ 250 mL of diluted drug product faster than 60 (±10) minutes.

[0337] Inclusion criteria Each potential subject must meet all of the following criteria to be included in the study: 1. Age ≥ 18 2. Patients with evaluable disease 2a. For Part 2, at least one measurable lesion that can be accurately assessed at baseline by CT (or magnetic resonance imaging [MRI] if CT is contraindicated) and suitable for repeat assessment by RECIST v1.1 3.2. Cancer type: Part 1 of the study: Patients with any type of advanced or refractory malignant solid tumor, except lymphoma, that is metastatic or unresectable and has previously received or been ineligible for standard treatment options, including appropriate targeted therapy (e.g., subjects with epidermal growth factor receptor (EGFR)-mutated NSCLC or with NSCLC with anaplastic lymphoma tyrosine kinase (ALK) rearrangements). Part 2 of the study: Histologically or cytologically confirmed diagnosis of one of the following unresectable stage III or IV malignant solid tumors and who have previously received or been ineligible for standard treatment options, including appropriate targeted therapy (e.g., subjects with EGFR-mutated NSCLC or with NSCLC with ALK rearrangements): NSCLC ○ PD-L1 high tumor samples (≥ 50% of tumor cells stained positive for PD-L1) by PD-L1 immunohistochemistry (IHC) testing performed by a local or central laboratory designated by the sponsor Confirmed disease progression during or after at least one prior treatment with platinum-containing chemotherapy for advanced / metastatic NSCLC - Have received 3 or fewer prior systemic regimens for the treatment of advanced NSCLC with disease progression on or after the last prior treatment (per RECIST v1.1). ●Bladder cancer (urothelial cancer) ●Renal cell carcinoma ●Stomach / esophageal cancer Melanoma ●SCLC ●MSI-H or dMMR CRC ○ MSI-H or dMMR by polymerase chain reaction (PCR), next-generation sequencing, or IHC testing performed by a local or central laboratory designated by the sponsor Progression after treatment with fluoropyrimidine, oxaliplatin, and irinotecan 4.Eastern Cooperative Oncology Group [ECOG] performance status is 0 or 1 5.2. Have the following organ and bone marrow function without blood product support: Hemoglobin ≥ 8.5 g / dL, ANC ≥ 1.5 x 109 / L, platelets ≥ 75.0 x 109 / L, AST and ALT ≤ 3 x ULN (or ≤ 4 x ULN for subjects with tumor involvement in the liver), total bilirubin ≤ 1.5 x ULNa, serum creatinine ≤ 1.5 x ULN, or calculated GFR ≥ 50 mL / min / 1.73 mm2, left ventricular ejection fraction within normal institutional limits; corrected QT interval (QTcF or QTcB) ≤ 480 msec based on the average of three assessments performed 5 (± 3) minutes apart. 6.1. Have thyroid function laboratory values ​​within the normal range. Note: If thyroid stimulating hormone (TSH) is not within the normal range, subjects may still be eligible if T3 (either total or free) and free T4 are within the normal range. 7. Females of childbearing potential must have a negative serum pregnancy test at screening using a high-sensitivity pregnancy test. 8. Willing to use contraception consistent with local regulations for subjects participating in the clinical study during and after the study through 5 months after the last dose of study medication. a. Females of childbearing potential must agree to use two highly effective methods of contraception (<1% failure rate per year when used consistently and correctly) consistent with local regulations. b. Unvasectomized men who are sexually active with women of childbearing potential must agree to the use of barrier contraception. c. The female and male must agree not to donate sperm or eggs (eggs, oocytes), respectively, during the study and after the study until 5 months after the last dose of study drug. 9. Must be willing and able to abide by the prohibitions and restrictions specified in this Protocol. 10. Each subject (or the subject's legal representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of the study and the procedures it will entail, and is willing to participate in the study. Consent must be obtained prior to the start of any study-related tests or procedures that are not part of the standard of care for the subject's disease. 11. Subjects enrolled in Part 2 must have tumor tissue available for correlative studies. Fresh tumor biopsy is preferred. Archival tissue must meet the following criteria: archival sections no more than 4 months old, stored at 2°C-8°C in the dark or archival tumor blocks no more than 5 years old from collection. Subjects without tissue meeting the aforementioned archival tissue criteria must undergo a fresh biopsy.

[0338] Exclusion criteria Potential subjects will be excluded from participation in this study if they meet any of the following criteria: 1. Have uncontrolled intercurrent illnesses including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure (New York Heart Association class III-IV), unstable angina, cardiac arrhythmias, poorly controlled hypertension or diabetes, or psychiatric / social conditions that would limit compliance with study requirements 2. Previous treatment with anti-PD-1 antibody, anti-PD-L1 antibody, or anti-PD-L2 antibody 3. Any local or systemic antineoplastic therapy, radiation therapy (excluding limited palliative radiation), or treatment with an investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, up to a maximum washout period of 28 days prior to initiation of study drug administration. 4. Standards revised by Amendment 2. 4.1. Has brain or leptomeningeal metastases unless asymptomatic, has been treated, has been stable for >4 weeks as confirmed by radiography with no evidence of cavitation or hemorrhage within the brain lesion, and does not require long-term (>2 weeks) systemic corticosteroid therapy. Subjects are not permitted to receive enzyme-inducing antiepileptic drugs. 5. At the time of treatment assignment, have not recovered from AEs (i.e., ≤ Grade 1 or baseline), except for alopecia, peripheral neuropathy related to prior anticancer therapy, and stable anemia (i.e., transfusion-free Hb ≥ 8.5 g / dL without the need for supportive transfusions within 2 weeks of screening) 6. Standards revised by Amendment 2 6.1. Active autoimmune disease requiring systemic corticosteroids or immunosuppressants, or a history of confirmed autoimmune disease. Note: Subjects with vitiligo or resolved childhood asthma / atopy are exceptions to this criterion. Subjects requiring intermittent use of bronchodilators or local steroid injections are not excluded from the study. Subjects with hypothyroidism stable on hormone replacement are not excluded from the study. Subjects with a history of transient autoimmune manifestations of acute infectious disease (e.g., Lyme arthritis) that resolved upon treatment of the pathogen are not excluded from the study. 7. Grade 3 or higher toxic effects from prior immunotherapy treatment 8. Has a history of any significant drug allergy (anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia) to protein-based therapies, or has a known allergy, hypersensitivity, or intolerance to JNJ-63723283 excipients (see Investigator Brochure) 9. Received immunosuppressive doses of systemic drugs such as corticosteroids (prednisone or equivalent at a dose of >10 mg / day) within 2 weeks of the first planned dose of study medication. 10. Females who are pregnant, breastfeeding, or planning to become pregnant during enrollment in this study or within 5 months after the last dose of study medication. 11. Men who plan to father a child while enrolled in this study or within 5 months after the last dose of study medication. 12. Has a condition whereby in the investigator's opinion participation would not be in the subject's best interest (e.g., would jeopardize well-being) or which may prevent, limit, or confound the evaluations specified in the protocol 13. Has undergone major surgery (e.g., requiring general anesthesia) within 4 weeks prior to dosing or has not fully recovered from surgery, or has surgery planned during the period during which the subject is expected to participate in the study or within 4 weeks after the last dose of study medication is administered. Note: Subjects scheduled for surgical treatment under local anesthesia are eligible to participate. 14. Standards revised by Amendment 2 Active or chronic hepatitis B or hepatitis C disease as determined by hepatitis B surface antigen (HBsAg), hepatitis B core antibody, or hepatitis C antibody (anti-HCV) positivity at screening. If positive, further testing at a quantitative level is required to rule out active infection. 15.Human immunodeficiency virus (HIV) antibody positivity history or HIV positivity at screening 16. Standards revised by Amendment 2 16.1. Received vaccination with a live vaccine within 28 days prior to the first dose of study drug. Annual inactivated influenza vaccine is acceptable. NOTE: Investigators should ensure that all study entry criteria are met at screening. If, after screening but before the first dose of study medication is given, the subject's clinical condition changes (including receipt of any available laboratory results or additional medical records) such that the subject is no longer able to meet all eligibility criteria, the subject should be excluded from participation in the study.

[0339] Permitted Drugs Throughout the study, the investigator may prescribe concomitant concomitant medications or treatments (including nutritional support, correction of metabolic disorders, optimal symptom control, and pain management) as deemed necessary to provide adequate supportive care. Subjects may continue use of bisphosphonates or denosumab for bone disease. Concomitant use of hormones for non-cancer-related conditions (e.g., insulin and hormone replacement therapy for diabetes) is permitted. Concomitant medications (e.g., acetaminophen / paracetamol or diphenhydramine) as deemed necessary by the investigator to provide adequate prophylaxis and management of IRR are permitted.

[0340] In addition, the following medications may be administered during the study: ● Standard supportive care therapy (antiemetics, antidiarrheals, anticholinergics, antispasmodics, antipyretics, antihistamines, analgesics, antibiotics and other antimicrobial agents, histamine receptor [H2] antagonists or proton pump inhibitors, and other medications intended to treat symptoms or signs of disease) as clinically indicated, according to institutional standards, and as deemed necessary by the investigator. Confirmed infectious complications should be treated with oral or IV antibiotics or other anti-infective agents as deemed appropriate by the investigator administering the treatment for the given infectious condition, according to standard institutional practice. Growth factor support for management of hematologic toxicities occurring during the recommended treatment period in accordance with National Comprehensive Cancer Network / European Organization for Research and Treatment of Cancer (NCCN / EORTC) guidelines.

[0341] Biomarkers Tumor tissue at baseline Available (archived or fresh) tumor tissue from consenting subjects will be requested by the sponsor or sponsor's designee for all subjects in Part 1 and is required from all subjects in Part 2 for biomarker analysis of PD-L1 expression by IHC. Prescreening for PD-L1 testing will be required for NSCLC subjects in Part 2 and may be performed by a local laboratory designated by the sponsor or by a central laboratory. Prescreening for MSI or dMMR testing will also be required for all CRC subjects by a local or central laboratory designated by the sponsor. Local test results will be primarily confirmed by the sponsor's designee's laboratory. In the event of discrepancy between local and central results, the central results will be used for analysis. Tumor tissue from the most recent tumor biopsy should be a formalin-fixed paraffin embedded (FFPE) tissue block collected within the past 5 years (preferred) or a minimum of 15 unstained slides that were processed within 4 months prior to study entry and stored at 2°C to 8°C in the dark. An additional 5 slides will be collected from CRC patients to support MSI-H analysis. If the facility does not have sufficient material, a fresh tumor biopsy of Part 2 subjects will be required. Whole blood will be collected from CRC patients to support tumor tissue MSI and dMMR testing. This blood collection may be discontinued with the development of the assay platform utilized for MSI / dMMR testing.

[0342] Physical description of the test drug Drug Product 1 (DP1): JNJ-63723283 DP1 study material supplied for this study is sterile, frozen in 8R glass vials with serum stoppers and aluminum seals with flip-off caps. Each vial of JNJ-63723283 clinical trial material is filled with 3.3 mL of a 10 mg / mL solution of JNJ-63723283 (10% overfill in 10 mM histidine, 8.0% (w / v) sucrose, 0.04% (w / v) polysorbate 20, 20 μg / ml EDTA, pH 6.5, e.g., deliverable amount of 30 mg / vial).

[0343] Drug Product 2 (DP2): JNJ-63723283 DP2 study material supplied for this study is a sterile lyophilized formulation in an 8R glass vial with a serum stopper and aluminum seal with a flip-off cap. Each vial of JNJ-63723283 clinical study material contains 90 mg per vial, which upon reconstitution is a 30 mg / mL solution of JNJ-63723283 in 10 mM histidine, 8.0% (w / v) sucrose, 0.04% polysorbate 20 (w / v), 20 μg / ml EDTA (pH 6.5).

[0344] DP3: JNJ-63723283 is also supplied as a sterile lyophilized formulation in 30 mL glass vials with flip-off caps, serum stoppers and aluminum seals. Each vial of JNJ-63723283 clinical study material contains 240 mg per vial, which upon reconstitution is a 30 mg / mL solution of JNJ-63723283 in 10 mM histidine, 8.0% (w / v) sucrose, 0.04% polysorbate 20 (w / v), 20 μg / ml EDTA (pH 6.5).

[0345] Example 2. Interim Results of a Phase 1 / 2 Study of JNJ-63723283 in Patients with Advanced Cancer (NCT02908906) At the clinical data cutoff of December 11, 2017, 38 patients were treated with study drug at 80 mg, 240 mg, 460 mg, or 800 mg once every 2 weeks (Q2W) or 480 mg once every 4 weeks (Q4W) in part 1 of the study. Demographics and baseline disease characteristics of patients in part 1 are shown in Table 1. Twelve (32%) patients continued treatment, and 26 (68%) discontinued study treatment (Table 2). Median duration of treatment was 51 days (range 1 to 297 days).

[0346] [Table 1]

[0347] [Table 2]

[0348] safety Dose-limiting toxicity (DLT) -240 mg Q2W: Grade 3 pleural effusion in a patient with NSCLC requiring pleurodesis on Study Day 26, as considered by the investigator, may be related to study drug due to its temporal relationship to study drug administration. -800 mg Q2W: Grade 5 dyspnea in a patient with thymoma secondary to myasthenia gravis 14 days after receiving a single dose of study drug. The most common AEs were anemia, fatigue, and vomiting (26% each; Table 3), and the most common grade 3-4 AEs were pleural effusion, hyponatremia, anemia, and hypertension (8% each). Serious AEs observed included pleural effusion (10%) and dyspnea (8%). - Immune-related AEs (irAEs) were reported in 37% of patients, with the most common irAEs being rash, hypothyroidism, and dyspnea (5% each). Three patients discontinued treatment due to possible / probable grade 3 treatment-related pneumonitis, myopathy, and increased alanine aminotransferase.

[0349] [Table 3]

[0350] Preliminary effect Four patients (NSCLC, gastric cancer, thymoma, and microsatellite unstable colon cancer) at the 240 mg dose Q2W and one patient (gastric cancer) at the 480 mg dose Q4W achieved a partial response (PR). The patient with thymoma had a delayed response 2 months after discontinuation from the study due to immune-mediated hepatitis. Eighteen (55%) response-evaluable patients achieved stable disease (SD) or better based on RECIST v1.1 (Table 4 shows investigator-assessed best overall response).

[0351] [Table 4]

[0352] Pharmacokinetics and Receptor Occupancy Serum concentrations of JNJ-63723283 in dosed subjects were consistent with linear and dose-proportional PK. Table 5 shows preliminary PK parameters of JNJ-63723283 in patients dosed with 80 mg, 240 mg, and 480 mg of JNJ-63723283 after the first dose. Figure 1 shows the mean serum concentration-time profile of JNJ-63723283. Circulating CD3 + Saturation of PD-1 receptors on T cells was demonstrated after the first dose and was maintained throughout the dosing interval at all dose levels (ranging from 80 mg to 480 mg) and frequencies (ranging from Q2W to Q4W). + The saturation rate (%) of PD-1 receptors on T cells is shown in Figure 2. Circulating CD3 + The saturation rate (%) of PD-1 receptors on T cells is shown in FIG.

[0353] [Table 5]

[0354] T cell function in treated patients PBMCs from treated patients showed near-maximal T cell activation in ex vivo SEB stimulation assays at all doses and time points tested. Figure 4 shows T cell activation in response to SEB before and 2 hours after dose 1 (D1-pre, D1-2 hours), at follow-up after dose 1 (D1-FU), before dose 2 (D2-pre), before dose 3 (D3-pre), and at the end of treatment (EOT) in patients receiving 240 mg antibody Q2W or 480 mg antibody Q4Q.

[0355] Methods: Modulation of JNJ-63723283 pharmacodynamics was characterized by assessing IL-2 expression in pre- and post-treatment ex vivo SEB (Staphylococcal Enterotoxin B) stimulated whole blood samples as an indicator of T cell activation. Briefly, blood samples were diluted 1:10 in RPMI 1640 medium and subsequently incubated for 4 days with 100ng / ml SEB + 10μg / ml JNJ-63723283 or isotype control, representing maximal and endogenous levels of IL-2 expression, respectively. The ratio of IL-2 expression levels between isotype and JNJ-63723283 ex vivo treated blood samples was then calculated to assess the degree of PD modulation, with a ratio of 1 indicating maximal T cell activation.

[0356] conclusion -JNJ-63723283 demonstrated a safety profile comparable to other anti-PD-1 antibodies. The RP2D of 240 mg Q2W will be evaluated in Phase 2, and the RP2D may be administered in an alternative regimen of 480 mg Q4W to allow flexibility in different clinical settings. • Preliminary antitumor activity was observed in previously treated patients with advanced cancer, with 5 patients (15%) achieving PR and 13 patients (39%) achieving SD. -JNJ-63723283 demonstrated linear and dose-proportional PK within the dose range evaluated. - JNJ-63723283 demonstrated saturable PD-1 RO and enhanced T cell activity in ex vivo SEB stimulation assays at all dose levels and across all dosing frequencies tested. • Additional dosage levels and dosing frequencies may be explored. ●This study is ongoing to further characterize the safety, PK, and clinical activity of JNJ-63723283.

[0357] Example 3. Interim Results of a Phase 1 / 2 Study of JNJ-63723283 in Patients with Advanced Cancer (NCT02908906) At the clinical data cutoff of December 4, 2018, 198 patients were treated with study drug DP1 at 80 mg, 240 mg, 460 mg, or 800 mg once every 2 weeks (Q2W), or study drug DP1 or DP2 at 480 mg once every 4 weeks (Q4W) in Part 1 / 2 of the study. Patient demographics and baseline disease characteristics of subjects in Part 1 and Part 2 are shown in Table 6.

[0358] [Table 6]

[0359] Table 7 shows the mutation status, number and type of prior therapies for melanoma patients in part 2. Table 8 shows the PD-L1 status, number and type of prior therapies for NSCLC patients in part 2. Table 9 shows MSI (microsatellite instability) status (central study outcome) in CRC.

[0360] [Table 7]

[0361] [Table 8]

[0362] [Table 9]

[0363] safety The most common TE-AEs (Treatment Emergent Adverse Events) reported were asthenia (22.2%), fatigue (19.2%), diarrhea (18.2%), dyspnea (18.2%), fever (17.7%), decreased appetite (16.7%), anemia (16.7%), nausea (15.7%), back pain (14.1%), increased ALT (12.6%), cough (12.1%), vomiting (11.6%), increased AST (11.6%), abdominal pain (10.1%), and constipation (10.1%). The most common grade 3-4 TE-AEs reported were anemia (6.6%), dyspnea (5.1%), pleural effusion (2.5%), pyrexia (5.1%), hyponatremia (3.0%), hyperamylasemia (2.5%), abdominal pain (2.5%), intestinal obstruction (2.5%), fatigue (2.5%), general physical health deterioration (2.5%), increased ALT (3.0%), increased AST (3.0%), increased GGT (3.0%), and hypertension (3.0%). Serious TEAEs were observed in nearly 50% of subjects. The most common TE SAEs were dyspnea (5.1%), pleural effusion (3.5%), ileus (3.5%), general physical health deterioration (3.0%), and pyrexia (3.0%). Immune-related AEs (irAEs) were reported in 35.9% of patients. Infusion-related reactions (IRRs) were reported in 14.1% of all subjects and 13.6% of subjects receiving the 240 mg Q2W dose. All but two IRRs were CTCAE grade 1 / 2. Only one subject did not complete the infusion due to an IRR of a grade 3 hypertensive event.

[0364] Table 10 shows a summary of adverse events reported in Parts 1 and 2. Table 11 shows adverse events occurring in >10% of subjects.

[0365] [Table 10]

[0366] [Table 11]

[0367] Preliminary efficacy observed in Part 2 subjects. One hundred forty patients at the 240 mg Q2W dose (NSCLC, melanoma, and MSI-H / dMMR CRC) were evaluable for response assessment based on the December 4, 2018 dataset. Four (2.9%) patients achieved a complete response (CR) and 23 (16.4%) achieved a partial response (PR). Seventy-three (52.1%) response-evaluable patients achieved stable disease (SD) or better based on RECIST v1.1. The following ORRs were observed by histologic subtype: 37.5% in NSCLC with PDL1+ ≥ 50%, 32.6% in nonuveal melanoma, and 12.5% ​​in MSI-H / dMMR CRC. In patients with centrally confirmed MSI-H CRC, the ORR increased to 16.7%. (Table 12 shows investigator-assessed best overall response and associated 80% confidence intervals.)

[0368] [Table 12]

[0369] conclusion - JNJ-63723283 demonstrated a safety profile in immune-sensitive advanced cancers comparable to other anti-PD-1 antibodies. -JNJ-63723283 demonstrated linear and dose-proportional PK within the dose range evaluated. - JNJ-63723283 demonstrated saturable PD-1 RO and enhanced T cell activity in ex vivo SEB stimulation assays at all dose levels and across all dosing frequencies tested. The RP2D of 240 mg Q2W will be evaluated in Phase 2, and the RP2D may be administered in an alternative regimen of 480 mg Q4W to allow flexibility in different clinical settings. • Additional dosage levels, route of administration (subcutaneous injection), and frequency of administration may be explored. Patients with advanced disease achieved an ORR of 19% overall. By histological subtype, the observed ORR was 37.5% in PDL1+ NSCLC, 32.6% in non-uveal melanoma, and 13% in MSI-H / dMMR. Follow-up is ongoing in the centrally ascertained MSI-H CRC cohort ●Studies are ongoing to further characterize the safety, PK, and clinical activity of JNJ-63723283 at the RP2D of 240 mg Q2W. The inventions described in the original claims of this application are listed below. [Invention 1] A method of treating cancer, the method comprising administering to a subject diagnosed with cancer an antagonist anti-PD1 antibody or an antigen-binding fragment thereof, the antibody comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6, at a dose of about 240 mg to about 480 mg. [Invention 2] 2. The method of claim 1, wherein the antagonist anti-PD-1 antibody, or the antigen-binding fragment thereof, is administered once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks. [Invention 3] the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, a) once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks at a dosage of approximately 240 mg; b) once every two weeks at a dosage of approximately 240 mg; c) once every three weeks at a dosage of approximately 240 mg; d) once every four weeks at a dosage of approximately 240 mg; e) Once every 5 weeks at a dosage of approximately 240 mg f) once every six weeks at a dosage of approximately 240 mg; g) once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks at a dosage of approximately 480 mg; h) once every two weeks at a dosage of approximately 480 mg i) once every three weeks at a dosage of approximately 480 mg; j) once every four weeks at a dosage of approximately 480 mg k) once every 5 weeks in a dosage of approximately 480 mg; or l) administered in a dosage of approximately 480 mg once every six weeks; The method according to claim 2. [Invention 4] The method according to claim 3, wherein the cancer is a solid tumor. [Invention 5] The method according to claim 4, wherein the solid tumor is an advanced solid tumor. [Invention 6] The method of invention 3, wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland cancer, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof. [Invention 7] The method of claim 6, wherein the subject is PD-1 axis naive. [Invention 8] The method of claim 6, wherein the subject has previously received one, two, or more therapeutic agents for treating the cancer. [Invention 9] The method of invention 8, wherein the one, two, or three or more prior therapeutic agents for treating the cancer are an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof. [Invention 10] The method of invention 8, wherein said subject is resistant, refractory, or resistant and refractory to said one, two, three or more previous therapeutic agents, or any combination thereof, for treating said cancer. [Invention 11] The method of invention 10, wherein the one, two, or three or more prior therapeutic agents for treating the cancer are an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof. [Invention 12] The method according to claim 6, wherein the cancer is PD-L1 positive. [Invention 13] 13. The method of claim 12, wherein the cancer is PD-L1 high. [Invention 14] The method according to claim 6, wherein the expression of PD-L1 in the cancer has not been determined. [Invention 15] The method of claim 6, wherein the cancer expresses mutant BRAF. [Invention 16] 16. The method of claim 15, wherein the mutant BRAF comprises a V600E mutation. [Invention 17] The method of claim 6, wherein the cancer expresses wild-type BRAF. [Invention 18] the antagonist anti-PD-1 antibody, or antigen-binding fragment thereof, a) administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); b) administered or provided for administration in a pharmaceutical composition comprising about 10 mg / ml of said antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) administered or provided for administration in a pharmaceutical composition comprising about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) provided for administration as a lyophilized formulation comprising about 90 mg to about 240 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients; e) provided for administration as a lyophilized formulation comprising about 90 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients; or f) provided for administration as a lyophilized formulation comprising about 240 mg of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, and one or more pharma- ceutically acceptable excipients; The method according to claim 6. [Invention 19] 19. The method of claim 18, wherein the lyophilized formulation of d), e), and / or f), upon reconstitution, comprises about 30 mg / ml of the antagonist anti-PD-1 antibody or antigen-binding fragment thereof, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5). [Invention 20] 7. The method of claim 6, wherein the antagonist anti-PD-1 antibody, or the antigen-binding fragment thereof, is administered by intravenous infusion. [Invention 21] 7. The method of claim 6, wherein the antagonist anti-PD-1 antibody, or the antigen-binding fragment thereof, is administered by subcutaneous injection. [Invention 22] The method of claim 6, wherein said method achieves an overall response rate (ORR) of at least about 15% in said group of subjects diagnosed with cancer. [Invention 23] 23. The method of claim 22, wherein said ORR of at least about 15% is achieved after a median treatment period of about 1.5 months or more. [Invention 24] 23. The method of claim 22, wherein said method achieves an ORR of at least about 19% in said group of subjects diagnosed with cancer. [Invention 25] The method according to claim 6, wherein the cancer is non-small cell lung cancer (NSCLC). [Invention 26] 26. The method of invention 25, wherein said method achieves an ORR of at least about 30% in a group of subjects diagnosed with PD-L1 high NSCLC, or an ORR of at least about 25% in a group of subjects in whom PD-L1 expression in said cancer has not been determined. [Invention 27] 27. The method according to claim 26, wherein said method achieves an ORR of at least about 35% in a group of subjects diagnosed with PD-L1-high NSCLC. [Invention 28] The method according to claim 6, wherein the cancer is melanoma. [Invention 29] 29. The method of claim 28, wherein said method achieves an ORR of at least about 25% in said group of subjects diagnosed with melanoma. [Invention 30] 30. The method according to claim 29, wherein the melanoma is non-uveal melanoma. [Invention 31] 31. The method of claim 30, wherein said method achieves an ORR of at least about 30% in said group of subjects diagnosed with non-uveal melanoma. [Invention 32] The method according to claim 6, wherein the CRC is microsatellite instability-high (MSI-H) CRC or mismatch repair deficient (dMMR) CRC, or a combination thereof. [Invention 33] 33. The method of claim 32, wherein the CRC is stage II CRC or stage III CRC. [Invention 34] 7. The method of claim 6, wherein the antagonist anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of SEQ ID NO:7 and a light chain variable region (VL) of SEQ ID NO:8. [Invention 35] 35. The method of claim 34, wherein the antagonist anti-PD-1 antibody, or the antigen-binding fragment thereof, is of the IgG1, IgG2, IgG3, or IgG4 isotype. [Invention 36] 36. The method of claim 35, wherein the antagonist anti-PD-1 antibody comprises a heavy chain of SEQ ID NO:9 and a light chain of SEQ ID NO:10. [Invention 37] 1. A pharmaceutical composition comprising: a) about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. The pharmaceutical composition comprising: [Invention 38] 38. The pharmaceutical composition of invention 37, wherein the lyophilized formulation of d), e), and / or f) upon reconstitution comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5). [Invention 39] A drug product comprising: a) about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. The drug product comprising: [Invention 40] 39. The drug product of claim 39, wherein the lyophilized formulations of d), e), and / or f), upon reconstitution, comprise about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5. [Invention 41] A drug product for the treatment of cancer, comprising: a) about 10 mg / ml to about 30 mg / ml of cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml of EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. The drug product comprising: [Invention 42] 42. The drug product of invention 41, wherein the lyophilized formulation of d), e), and / or f) upon reconstitution comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.5. [Invention 43] 42. The drug product of invention 41, wherein the cancer is lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, stomach cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland cancer, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof. [Invention 44] a) the NSCLC is PD-L1 high NSCLC; b) the CRC is an MSI-H CRC or a dMMR CRC; or c) the melanoma is a non-uveal melanoma; or any combination thereof, 44. A pharmaceutical product according to claim 43. [Invention 45] The drug product comprises: a) Once every two weeks at a dosage of approximately 240 mg, b) once every four weeks in a dosage of approximately 480 mg; or c) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after said initial dose, and then about 480 mg every 4 weeks thereafter; or d) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after said initial dose, and then about 240 mg every two weeks; 42. The pharmaceutical product according to claim 41, [Invention 46] 42. The drug product of claim 41, wherein said drug product is administered intravenously or subcutaneously or a combination thereof.

Claims

1. 1. A pharmaceutical composition for use in a method of treating cancer, comprising an antagonist anti-PD1 antibody comprising heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, LCDR3 of SEQ ID NO: 6, a heavy chain of SEQ ID NO: 9, and a light chain of SEQ ID NO: 10, wherein the antibody is administered to a subject diagnosed with cancer at a dose of about 240 mg once every two weeks to a dose of about 480 mg once every four weeks, and wherein the subject is PD-1 axis naive.

2. 2. The pharmaceutical composition of claim 1, wherein the antagonist anti-PD-1 antibody is administered once every two weeks, once every three weeks, or once every four weeks.

3. The pharmaceutical composition according to claim 1 or 2, wherein the cancer is a solid tumor.

4. The pharmaceutical composition of claim 3 , wherein the solid tumor is an advanced solid tumor.

5. 3. The pharmaceutical composition of claim 1 or 2, wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland cancer, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof.

6. The method of claim 5, wherein the subject has previously received one, two, or more therapeutic agents to treat the cancer.

7. 7. The pharmaceutical composition of claim 6, wherein the one, two, or more prior therapeutic agents for treating the cancer are an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof.

8. 7. The pharmaceutical composition of claim 6, wherein the subject is resistant, refractory, or resistant and refractory to the one, two, three or more previous therapeutic agents, or any combination thereof, for treating the cancer.

9. 9. The pharmaceutical composition of claim 8, wherein the one, two, or more prior therapeutic agents for treating the cancer are an anti-CTLA4 antibody, ipilimumab, a BRAF / MEK inhibitor, chemotherapy, or interferon alpha, or any combination thereof.

10. The pharmaceutical composition according to claim 5, wherein the cancer is PD-L1 positive.

11. The pharmaceutical composition according to claim 10, wherein the cancer is PD-L1 high.

12. The pharmaceutical composition of claim 5, wherein the expression of PD-L1 in the cancer has not been determined.

13. The pharmaceutical composition of claim 5 , wherein the cancer expresses mutant BRAF.

14. 14. The pharmaceutical composition of claim 13, wherein the mutant BRAF comprises a V600E mutation.

15. The pharmaceutical composition of claim 5 , wherein the cancer expresses wild-type BRAF.

16. the antagonist anti-PD-1 antibody a) adapted to be administered in a pharmaceutical composition comprising about 10 mg / ml to about 30 mg / ml of said antagonist anti-PD-1 antibody, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); b) adapted to be administered in a pharmaceutical composition comprising about 10 mg / ml of said antagonist anti-PD-1 antibody, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) adapted to be administered in a pharmaceutical composition comprising about 30 mg / ml of said antagonist anti-PD-1 antibody, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) adapted to be administered as a lyophilized formulation comprising about 90 mg to about 240 mg of said antagonist anti-PD-1 antibody and one or more pharma- ceutically acceptable excipients; e) adapted to be administered as a lyophilized formulation comprising about 90 mg of said antagonist anti-PD-1 antibody and one or more pharma- ceutically acceptable excipients; or f) adapted to be administered as a lyophilized formulation comprising about 240 mg of said antagonist anti-PD-1 antibody and one or more pharma- ceutically acceptable excipients; The pharmaceutical composition according to claim 5.

17. The freezing of d), e), and / or f).

17. The pharmaceutical composition of claim 16, wherein the dry formulation, upon reconstitution, comprises about 30 mg / ml of the antagonist anti-PD-1 antibody, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.

5.

18. The pharmaceutical composition of claim 5, wherein the antagonist anti-PD-1 antibody is administered by intravenous infusion.

19. The pharmaceutical composition of claim 5, wherein the antagonist anti-PD-1 antibody is administered by subcutaneous injection.

20. 6. The pharmaceutical composition of claim 5, wherein the method in which the pharmaceutical composition is used achieves an overall response rate (ORR) of at least about 15% in a group of subjects diagnosed with cancer.

21. 21. The pharmaceutical composition of claim 20, wherein the ORR of at least about 15% is achieved after a median treatment period of about 1.5 months or more.

22. 21. The pharmaceutical composition of claim 20, wherein the method achieves an ORR of at least about 19% in the group of subjects diagnosed with cancer.

23. The pharmaceutical composition of claim 5, wherein the cancer is non-small cell lung cancer (NSCLC).

24. 24. The pharmaceutical composition of claim 23, wherein the method in which the pharmaceutical composition is used achieves an ORR of at least about 30% in a subject population diagnosed with PD-L1 high NSCLC, or an ORR of at least about 25% in a subject population in which PD-L1 expression in the cancer has not been determined.

25. 25. The pharmaceutical composition of claim 24, wherein the method achieves an ORR of at least about 35% in a group of subjects diagnosed with PD-L1 high NSCLC.

26. The pharmaceutical composition of claim 5 , wherein the cancer is melanoma.

27. 27. The pharmaceutical composition of claim 26, wherein the method in which the pharmaceutical composition is used achieves an ORR of at least about 25% in the group of subjects diagnosed with melanoma.

28. 28. The pharmaceutical composition of claim 27, wherein the melanoma is non-uveal melanoma.

29. 30. The pharmaceutical composition of claim 28, wherein the method achieves an ORR of at least about 30% in the group of subjects diagnosed with non-uveal melanoma.

30. The pharmaceutical composition of claim 5, wherein the CRC is microsatellite instability-high (MSI-H) CRC or mismatch repair deficient (dMMR) CRC, or a combination thereof.

31. The pharmaceutical composition of claim 30, wherein the CRC is stage II CRC or stage III CRC.

32. The pharmaceutical composition of claim 1, wherein the antagonist anti-PD-1 antibody comprises a heavy chain variable region (VH) of SEQ ID NO:7 and a light chain variable region (VL) of SEQ ID NO:

8.

33. A pharmaceutical composition for the treatment of cancer, comprising: a) about 10 mg / ml to about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. Including, The pharmaceutical composition comprises: i) once every two weeks at a dosage of about 240 mg; ii) once every four weeks at a dosage of about 480 mg; or iii) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after said initial dose, and then about 480 mg once every 4 weeks thereafter; or iv) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after said initial dose, and then about 240 mg every two weeks; The pharmaceutical composition is administered.

34. The freezing of d), e), and / or f).

34. The pharmaceutical composition of claim 33, wherein the dry formulation, upon reconstitution, comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.

5.

35. A drug product for the treatment of cancer, comprising: a) about 10 mg / ml to about 30 mg / ml cetrelimab, about 10 mM histidine, 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20; and about 20 μg / ml EDTA (pH 6.5); b) about 10 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); c) about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA (pH 6.5); d) a lyophilized formulation comprising about 90 mg to about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; e) a lyophilized formulation comprising about 90 mg of cetrelimab and one or more pharma- ceutically acceptable excipients; or f) A lyophilized formulation comprising about 240 mg of cetrelimab and one or more pharma- ceutically acceptable excipients. Including, The drug product comprises: i) once every two weeks at a dosage of about 240 mg; ii) once every four weeks at a dosage of about 480 mg; or iii) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after said initial dose, and then about 480 mg once every 4 weeks thereafter; or iv) an initial dose of about 240 mg, followed by a second dose of about 480 mg 6 weeks after said initial dose, and then about 240 mg every two weeks; The drug product is administered.

36. The freezing of d), e), and / or f).

36. The drug product of claim 35, wherein the dry formulation, upon reconstitution, comprises about 30 mg / ml cetrelimab, about 10 mM histidine, about 8.0% (w / v) sucrose, about 0.04% (w / v) polysorbate-20, and about 20 μg / ml EDTA, pH 6.

5.

37. 37. The drug product of any one of claims 33 to 36, wherein the cancer is lung cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, gastrointestinal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, liver cancer, colorectal cancer (CRC), colon cancer, gallbladder cancer, biliary tract cancer, ovarian cancer, fallopian tube cancer, cervical cancer, peritoneal cancer, endometrial cancer, small cell lung cancer (SCLC), breast cancer, pancreatic cancer, renal cell carcinoma, Merkel cell carcinoma, primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), multiple myeloma, glioblastoma, urothelial carcinoma, salivary gland cancer, mesothelioma, anal cancer, prostate cancer, basal cell carcinoma, and advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof.

38. a) the NSCLC is PD-L1 high NSCLC; b) the CRC is an MSI-H CRC or a dMMR CRC; or c) the melanoma is a non-uveal melanoma; or any combination thereof, 38. The pharmaceutical product of claim 37.

39. 36. The drug product of claim 35, wherein the drug product is administered intravenously or subcutaneously, or a combination thereof.

Citation Information

Patent Citations

  • Low viscosity antibody composition

    JP2017105754A

  • Antibodies specifically binding PD-1 and their uses

    WO2017079112A1

  • Use of Anti-PD-1 antibody in the treatment of patients with colorectal cancer

    WO2017210637A1